Gulf Western Petroleum Announces Drilling of Fourth Frio Well in Texas Shamrock Project
Wednesday October 31, 12:31 pm ET
HOUSTON, Oct. 31, 2007 (PRIME NEWSWIRE) -- Gulf Western Petroleum Corporation (``Gulf Western'') (OTC BB: GWPC.OB) is pleased to announce they have been advised by the Operator that the drilling rig is on location at the Red Breast No. 1 drill site, and that the Red Breast No. 1 will spud today. After obtaining the log results from the first three wells, Gulf Western increased its position in the Shamrock Project in Dewitt County Texas by two additional wells, bringing their current participation in the Shamrock Project to five wells. The two additional wells are the Red Breast No. 1 and the Michael Collins No. 1. Both wells will target the same formation as the first three Frio prospects, the Jameson Sand at 3200'.
The Shamrock Project is a five well Frio-age prospect identified through 3-D seismic. Gulf Western currently has three wells drilled and completed. The wells are the Polinard-Lee No. 1 well, the Miller-Thomas No. 1 well, and the Bushmill No. 1 well. All three wells flow tested in excess of 300 Mcfd and are awaiting hook up to the sales line.
Frio-age wells have proven to be prolific natural gas producers throughout the Texas Gulf Coast region. Typical Frio wells produce at approximately 200 to 300 Mcf per day with estimated total recoverable reserves of approximately 500 million cubic feet to 1 billion cubic feet.
This press release may include forward-looking statements based on the Company's current expectations as to future events. The forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. For example, the extraction and sale of natural gas from the wells involves a number of costs and risks, which may limit our ability to generate cash flow from the wells. In addition, the business of Gulf Western Petroleum Corporation is subject to a number of risks typical of an oil and gas exploration and development company including, among other things, the inherent uncertainties associated with oil and gas exploration; laws, environmental, judicial, regulatory, political and competitive developments in areas in which Gulf Western Petroleum Corporation operates; and technological, mechanical and operational difficulties encountered in connection with Gulf Western Petroleum Corporation's activities.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Wednesday, October 31, 2007
DSKA News Alert
Duska Therapeutics Appoints Dr. Alan J. Tuchman to the Board of Directors
Wednesday October 31, 11:37 am ET
BALA CYNWYD, Pa., Oct. 31, 2007 (PRIME NEWSWIRE) -- Duska Therapeutics, Inc., (OTC BB: DSKA.OB), a biopharmaceutical company developing new medicines to treat cardiovascular diseases, announced today that it has appointed Alan J. Tuchman, M.D., M.B.A., as a board director.
Dr. Tuchman is Executive Chairman of Neurophysics, Inc., a medical technology company. He is also a partner in Xmark Opportunity Partners, a biotech investment fund. Dr. Tuchman is Clinical Professor of Neurology and Pharmacology at New York Medical College and the author of over 30 scientific papers and book chapters. He serves on the Scientific Advisory Board of Oncolytics Biotech, Inc., and was previously the President of the Epilepsy Society of Southern New York as well as Vice Dean for Clinical Affairs at New York Medical College. Dr. Tuchman received his medical degree from the University of Cincinnati, College of Medicine, and completed his neurology residency at the Mt. Sinai School of Medicine. He received his M.B.A. from Columbia University.
``With our pipeline of products, Dr. Tuchman's background as a biotech investor and clinical professor of neurology and pharmacology will provide excellent guidance to the company as a board director,'' stated Dr. James S. Kuo, Duska's Chairman and CEO.
About Duska Therapeutics, Inc.
Duska Therapeutics, Inc., develops new medicines to treat cardiovascular diseases by modulating the P2 receptor in the heart and lungs. In addition to ATPace(tm), (adenosine triphosphate injection) for the treatment and diagnosis of certain cardiac arrhythmias, Duska has drug development programs targeting chronic obstructive pulmonary disorders and cough, male infertility and mitigating the toxic effects of radiation exposure. For more information, visit Duska's website at http://www.duskatherapeutics.com.
Forward-Looking Statement: This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and certainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the early stage of Duska's drug development projects, Duska's limited financial resources and its need to raise additional capital to fund its ongoing working capital and drug development needs, the need for future clinical testing of Duska's drug candidates, uncertainties regarding the scope of the clinical testing that may be required by regulatory authorities and the outcomes of those tests, the significant time and expense that will be incurred in developing any of the potential commercial applications for Duska's P2R technologies, risks relating to the enforceability of any patents covering Duska's products and to the possible infringement of third party patents by those products, and the impact of third party reimbursement policies on the use of and pricing for Duska's products. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. All forward-looking statements are based upon information available to Duska on the date the statements are first published. Duska undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Wednesday October 31, 11:37 am ET
BALA CYNWYD, Pa., Oct. 31, 2007 (PRIME NEWSWIRE) -- Duska Therapeutics, Inc., (OTC BB: DSKA.OB), a biopharmaceutical company developing new medicines to treat cardiovascular diseases, announced today that it has appointed Alan J. Tuchman, M.D., M.B.A., as a board director.
Dr. Tuchman is Executive Chairman of Neurophysics, Inc., a medical technology company. He is also a partner in Xmark Opportunity Partners, a biotech investment fund. Dr. Tuchman is Clinical Professor of Neurology and Pharmacology at New York Medical College and the author of over 30 scientific papers and book chapters. He serves on the Scientific Advisory Board of Oncolytics Biotech, Inc., and was previously the President of the Epilepsy Society of Southern New York as well as Vice Dean for Clinical Affairs at New York Medical College. Dr. Tuchman received his medical degree from the University of Cincinnati, College of Medicine, and completed his neurology residency at the Mt. Sinai School of Medicine. He received his M.B.A. from Columbia University.
``With our pipeline of products, Dr. Tuchman's background as a biotech investor and clinical professor of neurology and pharmacology will provide excellent guidance to the company as a board director,'' stated Dr. James S. Kuo, Duska's Chairman and CEO.
About Duska Therapeutics, Inc.
Duska Therapeutics, Inc., develops new medicines to treat cardiovascular diseases by modulating the P2 receptor in the heart and lungs. In addition to ATPace(tm), (adenosine triphosphate injection) for the treatment and diagnosis of certain cardiac arrhythmias, Duska has drug development programs targeting chronic obstructive pulmonary disorders and cough, male infertility and mitigating the toxic effects of radiation exposure. For more information, visit Duska's website at http://www.duskatherapeutics.com.
Forward-Looking Statement: This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and certainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the early stage of Duska's drug development projects, Duska's limited financial resources and its need to raise additional capital to fund its ongoing working capital and drug development needs, the need for future clinical testing of Duska's drug candidates, uncertainties regarding the scope of the clinical testing that may be required by regulatory authorities and the outcomes of those tests, the significant time and expense that will be incurred in developing any of the potential commercial applications for Duska's P2R technologies, risks relating to the enforceability of any patents covering Duska's products and to the possible infringement of third party patents by those products, and the impact of third party reimbursement policies on the use of and pricing for Duska's products. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. All forward-looking statements are based upon information available to Duska on the date the statements are first published. Duska undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
CSUH Press Release
Celsius Turns Up the Temperature on Central Market Shelves
Wednesday October 31, 9:52 am ET
DELRAY BEACH, FL--(MARKET WIRE)--Oct 31, 2007 -- Celsius Holdings, Inc. (OTC BB: CSUH.OB) announced today that Celsius, the first healthy, calorie burning beverage that delivers sustained energy and great taste, based on trusted science, will now be available at Central Market, a specialty grocery retailer widely recognized as the destination for people who are passionate about food. The move expands the company's growing portfolio of accounts designed to distinguish Celsius as a "next generation" beverage.
"Celsius is an advanced product that delivers 'real' function that responds to today's demand for healthier products," said Erin Heit, Marketing VP, Celsius, Inc. "Central Market's eight stores in Texas will give Celsius another platform to reach upscale consumers who are seeking better-for-you foods and beverages. We both have a common goal of providing progressive options for consumers."
To create awareness and stimulate trial among Central Market customers, Celsius will conduct a series of in-store samplings, place advertisements in Central Market's circulars and create pallet displays.
About Celsius®
Celsius is a dietary supplement that in multiple clinical studies has been shown to burn over 100 calories, sustain energy and increase metabolism for up to 3 hours. In the most recent study conducted at the University of Oklahoma and released at the International Society of Sports Nutrition, Celsius was shown to burn more than 100 calories. Celsius contains a blend of ingredients including Green Tea with EGCG, Ginger, Calcium, Chromium, B Vitamins, and Vitamin C. Celsius contains none of the bad ingredients typically found in many drinks -- no sugar, no carbs, no preservatives, no artificial coloring, no high fructose corn syrup, no trans fats, and it has very little sodium. Celsius is available in 5 great-tasting flavors including Orange, Cola, Lemon-Lime, Wild Berry and Ginger Ale.
About Celsius Holdings, Inc.
Celsius Holdings, Inc. (OTC BB: CSUH.OB) manufactures Celsius through its wholly owned operating subsidiary, Celsius, Inc. Celsius Inc. is quickly gaining attention in the emerging $36 billion functional food and beverage industry, as the creator of the negative calorie beverage category and as a pioneer and leader in developing healthier beverage choices. Celsius, Inc. is building unique distribution strategies to gain broad penetration in all channels serving its consumer targets in all geographies. The continued mission of Celsius, Inc. is to create healthy refreshment through science and innovation and growth through passion and integrity. Celsius is available through multiple channels including grocery, drug, convenience stores, gyms and nutrition stores. Celsius is proudly carried by fine establishments such as Raleys, Kowalskis, Vitamin Shoppe, Hi-Health, Valero Corner Stores, Diamond Shamrock, Hannaford Supermarkets, Heinens, Snyders, Sweetbay Supermarkets, Discount Drug Mart, King Soopers, Krogers, Dillions, Fry's, Smiths, Gelsons, Market Baskets, and Central Markets. For more information about Celsius and Celsius, Inc., please visit http://www.celsius.com. For investor information, please visit http://www.redchip.com
Forward-Looking Statements
This press release may contain statements, which are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements contain projections of Celsius Holdings' future results of operations, financial position or state other forward-looking information. In some cases you can identify these statements by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will," and "would" or similar words. You should not rely on forward-looking statements because Celsius Holdings' actual results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: general economic and business conditions; our business strategy for expanding our presence in our industry; anticipated trends in our financial condition and results of operation; the impact of competition and technology change; existing and future regulations effecting our business, and other risks and uncertainties discussed in our reports Celsius Holdings files from time to time with the Securities and Exchange Commission. Celsius Holdings does not intend to and undertakes no duty to update the information contained in this press release.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Wednesday October 31, 9:52 am ET
DELRAY BEACH, FL--(MARKET WIRE)--Oct 31, 2007 -- Celsius Holdings, Inc. (OTC BB: CSUH.OB) announced today that Celsius, the first healthy, calorie burning beverage that delivers sustained energy and great taste, based on trusted science, will now be available at Central Market, a specialty grocery retailer widely recognized as the destination for people who are passionate about food. The move expands the company's growing portfolio of accounts designed to distinguish Celsius as a "next generation" beverage.
"Celsius is an advanced product that delivers 'real' function that responds to today's demand for healthier products," said Erin Heit, Marketing VP, Celsius, Inc. "Central Market's eight stores in Texas will give Celsius another platform to reach upscale consumers who are seeking better-for-you foods and beverages. We both have a common goal of providing progressive options for consumers."
To create awareness and stimulate trial among Central Market customers, Celsius will conduct a series of in-store samplings, place advertisements in Central Market's circulars and create pallet displays.
About Celsius®
Celsius is a dietary supplement that in multiple clinical studies has been shown to burn over 100 calories, sustain energy and increase metabolism for up to 3 hours. In the most recent study conducted at the University of Oklahoma and released at the International Society of Sports Nutrition, Celsius was shown to burn more than 100 calories. Celsius contains a blend of ingredients including Green Tea with EGCG, Ginger, Calcium, Chromium, B Vitamins, and Vitamin C. Celsius contains none of the bad ingredients typically found in many drinks -- no sugar, no carbs, no preservatives, no artificial coloring, no high fructose corn syrup, no trans fats, and it has very little sodium. Celsius is available in 5 great-tasting flavors including Orange, Cola, Lemon-Lime, Wild Berry and Ginger Ale.
About Celsius Holdings, Inc.
Celsius Holdings, Inc. (OTC BB: CSUH.OB) manufactures Celsius through its wholly owned operating subsidiary, Celsius, Inc. Celsius Inc. is quickly gaining attention in the emerging $36 billion functional food and beverage industry, as the creator of the negative calorie beverage category and as a pioneer and leader in developing healthier beverage choices. Celsius, Inc. is building unique distribution strategies to gain broad penetration in all channels serving its consumer targets in all geographies. The continued mission of Celsius, Inc. is to create healthy refreshment through science and innovation and growth through passion and integrity. Celsius is available through multiple channels including grocery, drug, convenience stores, gyms and nutrition stores. Celsius is proudly carried by fine establishments such as Raleys, Kowalskis, Vitamin Shoppe, Hi-Health, Valero Corner Stores, Diamond Shamrock, Hannaford Supermarkets, Heinens, Snyders, Sweetbay Supermarkets, Discount Drug Mart, King Soopers, Krogers, Dillions, Fry's, Smiths, Gelsons, Market Baskets, and Central Markets. For more information about Celsius and Celsius, Inc., please visit http://www.celsius.com. For investor information, please visit http://www.redchip.com
Forward-Looking Statements
This press release may contain statements, which are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements contain projections of Celsius Holdings' future results of operations, financial position or state other forward-looking information. In some cases you can identify these statements by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will," and "would" or similar words. You should not rely on forward-looking statements because Celsius Holdings' actual results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: general economic and business conditions; our business strategy for expanding our presence in our industry; anticipated trends in our financial condition and results of operation; the impact of competition and technology change; existing and future regulations effecting our business, and other risks and uncertainties discussed in our reports Celsius Holdings files from time to time with the Securities and Exchange Commission. Celsius Holdings does not intend to and undertakes no duty to update the information contained in this press release.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
GWPC News Alert
Gulf Western Petroleum Completes Red Breast # 1 Gas Well: Four for Four in Texas Shamrock Project
Wednesday October 31, 2:00 am ET
HOUSTON, TX, Oct. 31 /PRNewswire-FirstCall/ - Gulf Western Petroleum Corporation ("Gulf Western") (OTCBB: GWPC/Frankfurt: GER), is pleased to announce that they have been advised by the Operator that the Red Breast # 1 Frio well is drilled, completed and currently undergoing testing. The Red Breast was drilled and casing set to 3120', and will be produced from 2896' to 2906'. The drilling rig has moved to the Michael Collins # 1 location which is scheduled to spud today. The Michael Collins will be the fifth and final well in the Shamrock Project.
The Shamrock Project is a five well Frio-age prospect identified through 3-D seismic. The target objective is the Jameson Sand at 3200'. Frio-age wells have proven to be prolific natural gas producers throughout the Texas Gulf Coast region. Typical Frio wells produce at approximately 200 to 300 Mcf per day with estimated total recoverable reserves of approximately 500 million cubic feet to 1 Billion cubic feet.
Gulf Western currently has three of the five wells completed and tested. These wells are the Polinard-Lee # 1 well; the Miller-Thomas # 1 well; and the Bushmill # 1 well. All three wells flow tested in excess of 300 Mcfd and are awaiting meters to be set at the delivery point of the pipeline. The extension of the gathering system that is required for the two additional wells is currently under construction and all five wells are scheduled for hook up within the next ten to fifteen days.
This press release may include forward-looking statements based on the Company's current expectations as to future events. The forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. For example, the extraction and sale of natural gas from the wells involves a number of costs and risks, which may limit our ability to generate cash flow from the wells. In addition, the business of Gulf Western Petroleum Corporation is subject to a number of risks typical of an oil and gas exploration and development company including, among other things, the inherent uncertainties associated with oil and gas exploration; laws, environmental, judicial, regulatory, political and competitive developments in areas in which Gulf Western Petroleum Corporation operates; and technological, mechanical and operational difficulties encountered in connection with Gulf Western Petroleum Corporation's activities.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Wednesday October 31, 2:00 am ET
HOUSTON, TX, Oct. 31 /PRNewswire-FirstCall/ - Gulf Western Petroleum Corporation ("Gulf Western") (OTCBB: GWPC/Frankfurt: GER), is pleased to announce that they have been advised by the Operator that the Red Breast # 1 Frio well is drilled, completed and currently undergoing testing. The Red Breast was drilled and casing set to 3120', and will be produced from 2896' to 2906'. The drilling rig has moved to the Michael Collins # 1 location which is scheduled to spud today. The Michael Collins will be the fifth and final well in the Shamrock Project.
The Shamrock Project is a five well Frio-age prospect identified through 3-D seismic. The target objective is the Jameson Sand at 3200'. Frio-age wells have proven to be prolific natural gas producers throughout the Texas Gulf Coast region. Typical Frio wells produce at approximately 200 to 300 Mcf per day with estimated total recoverable reserves of approximately 500 million cubic feet to 1 Billion cubic feet.
Gulf Western currently has three of the five wells completed and tested. These wells are the Polinard-Lee # 1 well; the Miller-Thomas # 1 well; and the Bushmill # 1 well. All three wells flow tested in excess of 300 Mcfd and are awaiting meters to be set at the delivery point of the pipeline. The extension of the gathering system that is required for the two additional wells is currently under construction and all five wells are scheduled for hook up within the next ten to fifteen days.
This press release may include forward-looking statements based on the Company's current expectations as to future events. The forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. For example, the extraction and sale of natural gas from the wells involves a number of costs and risks, which may limit our ability to generate cash flow from the wells. In addition, the business of Gulf Western Petroleum Corporation is subject to a number of risks typical of an oil and gas exploration and development company including, among other things, the inherent uncertainties associated with oil and gas exploration; laws, environmental, judicial, regulatory, political and competitive developments in areas in which Gulf Western Petroleum Corporation operates; and technological, mechanical and operational difficulties encountered in connection with Gulf Western Petroleum Corporation's activities.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
OLGX News Alert
Osteologix to Present at the Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference
Tuesday October 30, 4:16 pm ET
Live Webcast Scheduled November 5 at 12:20 p.m. ET
SAN FRANCISCO--(BUSINESS WIRE)--Osteologix Inc. (OTC BB: OLGX.OB), a specialty pharmaceutical company developing innovative therapies for the treatment and prevention of musculoskeletal diseases, today announced that Philip J. Young, President and CEO of Osteologix, will present a corporate overview Monday, November 5, at 12:20 p.m. EST during the Rodman and Renshaw Acumen BioFin 9th Annual Healthcare Conference at the New York Palace Hotel in New York City. A live audio webcast and slide presentation will be available via the internet by visiting www.osteologix.com and clicking the link provided under ?Latest News?. An archived presentation will be available for 90 days.
About Osteologix
Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. The Company?s vision is to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis. Its lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.
About NB S101
NB S101 is a novel dual acting bone agent, or DABA, the active component of which significantly improves bone density and reduces fracture risk. In preclinical studies, NB S101 has demonstrated significant beneficial effects by reducing bone resorption and increasing bone formation and bone mineralization. This dual action on bone? a significant medical need? suggests that NB S101 could fundamentally change the treatment paradigm of patients with osteoporosis. Importantly, NB S101 helps to build bone in a manner similar to the body?s own metabolic processes by rebalancing bone metabolism in a way that favors strong bone development. Osteologix has a competitive intellectual property position. A key patent for NB S101 has been issued in EU providing protection out to 2024, with US patents published and currently pending.
The NB S101 Program and the STRONG Study
Osteologix has conducted extensive preclinical and clinical drug research with its proprietary DABA, NB S101. The Phase II STRONG Study evaluating NB S101 is a randomized, double-blind, placebo-controlled, parallel-group dose response study in 289 postmenopausal women. The results will provide data on the effects of NB S101 on bone metabolism, bone mineral density, safety, tolerability and pharmacokinetics. The primary endpoint in the trial is the change in patients' bone resorption, as measured by the biochemical marker CTX-1. Data from this trial will be reported in the fourth quarter of 2007.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Tuesday October 30, 4:16 pm ET
Live Webcast Scheduled November 5 at 12:20 p.m. ET
SAN FRANCISCO--(BUSINESS WIRE)--Osteologix Inc. (OTC BB: OLGX.OB), a specialty pharmaceutical company developing innovative therapies for the treatment and prevention of musculoskeletal diseases, today announced that Philip J. Young, President and CEO of Osteologix, will present a corporate overview Monday, November 5, at 12:20 p.m. EST during the Rodman and Renshaw Acumen BioFin 9th Annual Healthcare Conference at the New York Palace Hotel in New York City. A live audio webcast and slide presentation will be available via the internet by visiting www.osteologix.com and clicking the link provided under ?Latest News?. An archived presentation will be available for 90 days.
About Osteologix
Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. The Company?s vision is to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis. Its lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.
About NB S101
NB S101 is a novel dual acting bone agent, or DABA, the active component of which significantly improves bone density and reduces fracture risk. In preclinical studies, NB S101 has demonstrated significant beneficial effects by reducing bone resorption and increasing bone formation and bone mineralization. This dual action on bone? a significant medical need? suggests that NB S101 could fundamentally change the treatment paradigm of patients with osteoporosis. Importantly, NB S101 helps to build bone in a manner similar to the body?s own metabolic processes by rebalancing bone metabolism in a way that favors strong bone development. Osteologix has a competitive intellectual property position. A key patent for NB S101 has been issued in EU providing protection out to 2024, with US patents published and currently pending.
The NB S101 Program and the STRONG Study
Osteologix has conducted extensive preclinical and clinical drug research with its proprietary DABA, NB S101. The Phase II STRONG Study evaluating NB S101 is a randomized, double-blind, placebo-controlled, parallel-group dose response study in 289 postmenopausal women. The results will provide data on the effects of NB S101 on bone metabolism, bone mineral density, safety, tolerability and pharmacokinetics. The primary endpoint in the trial is the change in patients' bone resorption, as measured by the biochemical marker CTX-1. Data from this trial will be reported in the fourth quarter of 2007.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
SPDV News Alert
SpaceDev Announces Timing of Fiscal Third Quarter 2007 Earnings Release and Conference Call
Tuesday October 30, 4:18 pm ET
POWAY, CA--(MARKET WIRE)--Oct 30, 2007 -- SpaceDev, Inc. (OTC BB: SPDV.OB) will host a conference call to discuss its third quarter 2007 financial results on Tuesday, November 13, 2007, at 10:30 a.m. EST. The Company expects to file its third quarter Form 10-QSB with the Securities and Exchange Commission, and issue a related press release, on Monday, November 12.
SpaceDev invites all those interested in hearing management's discussion of the quarter to join the call by dialing (866) 289-3234 and entering the PIN 8832 when prompted. A replay of the conference call will also be available for 7 days through the investor relations section of SpaceDev's website, www.spacedev.com.
About SpaceDev
SpaceDev, Inc. is a space technology/aerospace company that creates and sells affordable and innovative space products and mission solutions. For more information, visit www.spacedev.com.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Tuesday October 30, 4:18 pm ET
POWAY, CA--(MARKET WIRE)--Oct 30, 2007 -- SpaceDev, Inc. (OTC BB: SPDV.OB) will host a conference call to discuss its third quarter 2007 financial results on Tuesday, November 13, 2007, at 10:30 a.m. EST. The Company expects to file its third quarter Form 10-QSB with the Securities and Exchange Commission, and issue a related press release, on Monday, November 12.
SpaceDev invites all those interested in hearing management's discussion of the quarter to join the call by dialing (866) 289-3234 and entering the PIN 8832 when prompted. A replay of the conference call will also be available for 7 days through the investor relations section of SpaceDev's website, www.spacedev.com.
About SpaceDev
SpaceDev, Inc. is a space technology/aerospace company that creates and sells affordable and innovative space products and mission solutions. For more information, visit www.spacedev.com.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
BSRC News Alert
BioSolar Presenting at RedChip SmallCap Conference
Tuesday October 30, 9:05 am ET
Will Discuss Successful Prototype of Bio-Based Photovoltaic Backsheet and Strategic Positioning for Rapid Market Penetration
SANTA CLARITA, CA--(MARKET WIRE)--Oct 30, 2007 -- BioSolar(TM), Inc. (OTC BB: BSRC.OB), developer of a breakthrough technology to produce bioplastic materials from renewable plant sources that reduces the cost of photovoltaic solar cells, today announced that the company has accepted an invitation to speak at the RedChip SmallCap Investor Conference in Orlando, FL this coming Saturday, November 3rd, 2007, at 11:25 AM.
Commenting on his upcoming presentation, Dr. David Lee, the company's CEO, noted that as oil prices continue their record breaking rise, and as other key commodities used in the manufacture of solar cells become scarcer, profit pressures on photovoltaic manufacturers are forcing them to rapidly adopt new technologies and materials to bolster their profits.
"We are seeing this combination of factors in the industry drive the solar cell manufacturers to be much more creative as they seek out other ways of reducing the overall cost of the finished product," said Dr. Lee. "BioSolar has developed a bio-based plastic material for the backsheet component of the solar cell that represents a huge cost saving -- indications are that it's as much as 50% savings over the current pricing of petroleum-based plastics currently being used."
BioSolar's presentation will be at 11:25 AM and the company's executives will be available to meet with investors in a one-on-one situation throughout the rest of the day. The RedChip Small Cap Conference will be held at the Hyatt Regency Grand Cypress Hotel located at One Grand Cypress Blvd in Orlando.
A live web cast of the presentation will be accessible at http://www.redchip.com. The conference is free for private investors, fund-managers, retail brokers, and analysts. Register online at http://www.redchip.com.
About BioSolar, Inc.
BioSolar, Inc. is developing a breakthrough technology to produce bioplastic materials from renewable plant sources that will reduce the cost per watt of solar cells. Most of the solar industry is focused on photovoltaic efficiency to reduce cost. BioSolar is the first company to introduce a new dimension of cost reduction by replacing petroleum-based plastic solar cell components with durable bio-based plastics. To learn more about BioSolar, please visit our website at http://www.biosolar.com.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Tuesday October 30, 9:05 am ET
Will Discuss Successful Prototype of Bio-Based Photovoltaic Backsheet and Strategic Positioning for Rapid Market Penetration
SANTA CLARITA, CA--(MARKET WIRE)--Oct 30, 2007 -- BioSolar(TM), Inc. (OTC BB: BSRC.OB), developer of a breakthrough technology to produce bioplastic materials from renewable plant sources that reduces the cost of photovoltaic solar cells, today announced that the company has accepted an invitation to speak at the RedChip SmallCap Investor Conference in Orlando, FL this coming Saturday, November 3rd, 2007, at 11:25 AM.
Commenting on his upcoming presentation, Dr. David Lee, the company's CEO, noted that as oil prices continue their record breaking rise, and as other key commodities used in the manufacture of solar cells become scarcer, profit pressures on photovoltaic manufacturers are forcing them to rapidly adopt new technologies and materials to bolster their profits.
"We are seeing this combination of factors in the industry drive the solar cell manufacturers to be much more creative as they seek out other ways of reducing the overall cost of the finished product," said Dr. Lee. "BioSolar has developed a bio-based plastic material for the backsheet component of the solar cell that represents a huge cost saving -- indications are that it's as much as 50% savings over the current pricing of petroleum-based plastics currently being used."
BioSolar's presentation will be at 11:25 AM and the company's executives will be available to meet with investors in a one-on-one situation throughout the rest of the day. The RedChip Small Cap Conference will be held at the Hyatt Regency Grand Cypress Hotel located at One Grand Cypress Blvd in Orlando.
A live web cast of the presentation will be accessible at http://www.redchip.com. The conference is free for private investors, fund-managers, retail brokers, and analysts. Register online at http://www.redchip.com.
About BioSolar, Inc.
BioSolar, Inc. is developing a breakthrough technology to produce bioplastic materials from renewable plant sources that will reduce the cost per watt of solar cells. Most of the solar industry is focused on photovoltaic efficiency to reduce cost. BioSolar is the first company to introduce a new dimension of cost reduction by replacing petroleum-based plastic solar cell components with durable bio-based plastics. To learn more about BioSolar, please visit our website at http://www.biosolar.com.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday, October 29, 2007
CABN News Alert
Carbon Sciences, Inc. to Present at the RedChip Orlando Small Cap Investor Conference November 3, 2007
Monday October 29, 6:48 am ET
SANTA BARBARA, CA--(MARKET WIRE)--Oct 29, 2007 -- Carbon Sciences, Inc. (Other OTC: CABN.OB), the developer of a breakthrough technology to transform earth destroying carbon dioxide (CO2) into earth friendly carbon products, today announced that Derek McLeish, CEO, will deliver a presentation to investors about strategy and business prospects at the RedChip Small Cap Investor Conference on Saturday, November 3, 2007 at 11:50 A.M. (EDT).
"Since we became a public company two months ago, we have received many investor inquiries about our company and business plan. The RedChip conference will be our first investor conference, and I am very excited to share our plan and strategy with a wide audience of investors," stated Mr. McLeish.
The RedChip Small Cap Conference will be held at the Hyatt Regency Grand Cypress Hotel located at One Grand Cypress Blvd in Orlando. Carbon Sciences executives will be available to meet with investors throughout the event held on November 3.
A live web cast of the presentation will be accessible at http://www.redchip.com. The conference is free for private investors, fund-managers, retail brokers, and analysts. Register online at http://www.redchip.com.
About Carbon Sciences, Inc.
Carbon Sciences, Inc. is developing an innovative technology to transform earth destroying carbon dioxide (CO2) into earth friendly carbon products. We call this breakthrough GreenCarbon(TM) Technology. By eliminating harmful CO2 from human created sources, such as power plants and industrial factories, we will help reduce global warming. By transforming harmful CO2 into useful carbon products, such as building materials, our patent-pending technology will help create environmentally friendly products and industries. To learn more about the Company, please visit our website at http://www.carbonsciences.com.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday October 29, 6:48 am ET
SANTA BARBARA, CA--(MARKET WIRE)--Oct 29, 2007 -- Carbon Sciences, Inc. (Other OTC: CABN.OB), the developer of a breakthrough technology to transform earth destroying carbon dioxide (CO2) into earth friendly carbon products, today announced that Derek McLeish, CEO, will deliver a presentation to investors about strategy and business prospects at the RedChip Small Cap Investor Conference on Saturday, November 3, 2007 at 11:50 A.M. (EDT).
"Since we became a public company two months ago, we have received many investor inquiries about our company and business plan. The RedChip conference will be our first investor conference, and I am very excited to share our plan and strategy with a wide audience of investors," stated Mr. McLeish.
The RedChip Small Cap Conference will be held at the Hyatt Regency Grand Cypress Hotel located at One Grand Cypress Blvd in Orlando. Carbon Sciences executives will be available to meet with investors throughout the event held on November 3.
A live web cast of the presentation will be accessible at http://www.redchip.com. The conference is free for private investors, fund-managers, retail brokers, and analysts. Register online at http://www.redchip.com.
About Carbon Sciences, Inc.
Carbon Sciences, Inc. is developing an innovative technology to transform earth destroying carbon dioxide (CO2) into earth friendly carbon products. We call this breakthrough GreenCarbon(TM) Technology. By eliminating harmful CO2 from human created sources, such as power plants and industrial factories, we will help reduce global warming. By transforming harmful CO2 into useful carbon products, such as building materials, our patent-pending technology will help create environmentally friendly products and industries. To learn more about the Company, please visit our website at http://www.carbonsciences.com.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
BFNH News Alert
RedChip Visibility Issues Research Update On BioForce Nanosciences Holdings, Inc.
Friday October 26, 9:58 am ET
ORLANDO, Fla., Oct. 26, 2007 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., announced that it has issued a second quarter research update on BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH.OB), a developer of nanotechnology instruments, consumables, and applications for the life sciences industry, announced the completion of a financing transaction valued up to $3.45 million. The transaction entailed sales to an institutional investor of Series A 8% Convertible Preferred Stock at $0.50 per share and a series of warrants with exercise prices ranging from $0.50 to $1.25 per share. Notably, the transaction is structured at a fixed price and therefore protects the interests of current shareholders.
``In summary, we continue to believe BFNH offers a compelling investment opportunity for those seeking exposure to micro-cap nanotechnology equities. With a current market cap of less than $16 million, BFHN is undervalued given the expected trajectory of near-term revenue growth and the large ultimate market potential of the Company's product offering. Using sales of AFMs as a proxy for market size and assuming approximately 8,000 AFM sales to date yields a potential market of $1.3 billion (8,000 systems x $160,000 per system) for the NeN system, or $800 million assuming a lower sales target (5,000 systems). Note this analysis conservatively does not include 1) follow on sales of consumables (e.g. the ''ink cartridge`` and ''paper``), 2) potential price increases for high throughput product enhancements or 3) intellectual property related to its ViriChip and Chip-on-a-Tip product development initiatives.''
To receive a complimentary copy of the RedChip Visibility research update for BFNH, please visit:
BFNH Q2 2007 Update
About RedChip Companies, Inc.
RedChip Companies is an international small-cap research and financial public relations firm with offices in Beijing and Orlando and affiliates in New York and San Diego. RedChip delivers measurable results for its clients through its extensive international market expertise as well as its comprehensive platform of products: RedChip Research, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences held throughout the United States, RedChip Radio, and RedChip TV.
To learn more about RedChip's products and services please visit:
http://www.redchip.com/visibility/services.asp
Disclosures
The analysts contributing to this report do not hold any shares of BFNH. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. RedChip certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change. BFNH is a client of RedChip Visibility, a division of RedChip Companies. BFNH paid RedChip Visibility $32,400 for the RedChip Visibility Research Program, which includes this report. RedChip Visibility has been contracted by BFNH to increase investor awareness of BFNH to the small-cap equity community. These services may include investor conferences and digital and print distribution of BFNH investor related materials. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip was hired by the Company and receives a monthly fee of $5,500 and warrants to purchase 80,000 shares of the Company's common stock.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Friday October 26, 9:58 am ET
ORLANDO, Fla., Oct. 26, 2007 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., announced that it has issued a second quarter research update on BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH.OB), a developer of nanotechnology instruments, consumables, and applications for the life sciences industry, announced the completion of a financing transaction valued up to $3.45 million. The transaction entailed sales to an institutional investor of Series A 8% Convertible Preferred Stock at $0.50 per share and a series of warrants with exercise prices ranging from $0.50 to $1.25 per share. Notably, the transaction is structured at a fixed price and therefore protects the interests of current shareholders.
``In summary, we continue to believe BFNH offers a compelling investment opportunity for those seeking exposure to micro-cap nanotechnology equities. With a current market cap of less than $16 million, BFHN is undervalued given the expected trajectory of near-term revenue growth and the large ultimate market potential of the Company's product offering. Using sales of AFMs as a proxy for market size and assuming approximately 8,000 AFM sales to date yields a potential market of $1.3 billion (8,000 systems x $160,000 per system) for the NeN system, or $800 million assuming a lower sales target (5,000 systems). Note this analysis conservatively does not include 1) follow on sales of consumables (e.g. the ''ink cartridge`` and ''paper``), 2) potential price increases for high throughput product enhancements or 3) intellectual property related to its ViriChip and Chip-on-a-Tip product development initiatives.''
To receive a complimentary copy of the RedChip Visibility research update for BFNH, please visit:
BFNH Q2 2007 Update
About RedChip Companies, Inc.
RedChip Companies is an international small-cap research and financial public relations firm with offices in Beijing and Orlando and affiliates in New York and San Diego. RedChip delivers measurable results for its clients through its extensive international market expertise as well as its comprehensive platform of products: RedChip Research, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences held throughout the United States, RedChip Radio, and RedChip TV.
To learn more about RedChip's products and services please visit:
http://www.redchip.com/visibility/services.asp
Disclosures
The analysts contributing to this report do not hold any shares of BFNH. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. RedChip certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change. BFNH is a client of RedChip Visibility, a division of RedChip Companies. BFNH paid RedChip Visibility $32,400 for the RedChip Visibility Research Program, which includes this report. RedChip Visibility has been contracted by BFNH to increase investor awareness of BFNH to the small-cap equity community. These services may include investor conferences and digital and print distribution of BFNH investor related materials. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip was hired by the Company and receives a monthly fee of $5,500 and warrants to purchase 80,000 shares of the Company's common stock.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
ACCY News Alert
Discover Florida Small-Cap Companies At the Upcoming RedChip Orlando Investor Conference
Friday October 26, 9:22 am ET
CEOs of Twenty-One Small-Cap Companies Representing Fifteen Industries Will Deliver Presentations From 8:30 a.m.-5:00 p.m., November 3, 2007 At the Hyatt Regency Grand Cypress in Orlando, FL
ORLANDO, Fla., Oct. 26, 2007 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., today announced that the CEOs and executive teams of twenty-one small-cap companies will present at RedChip's Small-Cap Investor Conference in Orlando, Florida, November 3, 2007. The Conference will feature RedChip TV(tm) interviews, networking events, and financial presentations before hundreds of investment bankers, fund managers, institutional and accredited investors, research analysts, and high net worth individuals.
Investors all over the world will be able to see and hear presenters at the conference in real time at http://www.redchip.com. Additionally, investors will have the opportunity to meet one-on-one with the CEOs of presenting companies as well as the RedChip Elite(tm), the Company's top retail brokers, institutional brokers, and fund managers.
The Conference will include presentations from: GeoPharma Inc. (NasdaqCM:GORX - News), Worldwide Manufacturing USA, Inc. (OTC BB:WWMU.OB - News), SpaceDev, Inc. (OTC BB:SPDV.OB - News), Alternative Construction Technologies, Inc. (OTC BB: ACCY.OB), NaturalNano, Inc. (OTC BB:NNAN.OB - News), Ener1, Inc. (OTC BB:ENEI.OB - News), The Amacore Group, Inc. (OTC BB:ACGI.OB - News), Pressure BioSciences, Inc. (NasdaqCM:PBIO - News), Sharps Compliance Corporation (OTC BB:SCOM.OB - News), Advant-e Corporation (OTC BB:AVEE.OB - News), Bridgeline Software, Inc. (NasdaqCM:BLSW - News), Santa Fe Gold Corporation (OTC BB:SFEG.OB - News), BioSolar, Inc (OTC BB:BSRC.OB - News), Carbon Sciences, Inc. (OTC BB:CABN.OB - News), Celsius Holdings, Inc. (OTC BB:CSUH.OB - News), Left Behind Games, Inc. (OTC BB:LFBG.OB - News), Duska Therapeutics, Inc. (OTC BB:DSKA.OB - News), and TMT Capital Corporation (OTC BB:TMTP.OB - News) and Onstream Media Corporation (NasdaqCM:ONSM - News).
The RedChip Conference will feature companies representing the following industries: Biotechnology, Nanotechnology, Environmental Restoration, Diagnostic Substances, Alternative Energy, Communication Equipment, Oil & Gas, Consumer Services, Business Services, Internet Software & Services, Management Services, Specialty Auto Parts, and more.
The conference is free for private investors, fund-managers, retail brokers, and analysts. Space is limited; to register online please visit:
http://www.redchip.com/visibility/conferencePages/Orlando2007/conferenceMain.asp?page=attendees_register&from=OrlandoConf2007Homepage or call 1-800-RedChip (733-2447) ext. 100.
About RedChip Companies, Inc.
RedChip Companies is an international small-cap research and financial public relations firm with offices in Beijing and Orlando and affiliates in New York and San Diego. RedChip delivers measurable results for its clients through its extensive international market expertise as well as its comprehensive platform of products: RedChip Research(tm), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences held throughout the United States, RedChip Radio(tm) and RedChip TV(tm). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/services.asp.
``Discovering Tomorrow's Blue Chips Today.''(tm)
The RedChip Companies Inc. logo is available at
http://www.primenewswire.com/newsroom/prs/?pkgid=2761
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Friday October 26, 9:22 am ET
CEOs of Twenty-One Small-Cap Companies Representing Fifteen Industries Will Deliver Presentations From 8:30 a.m.-5:00 p.m., November 3, 2007 At the Hyatt Regency Grand Cypress in Orlando, FL
ORLANDO, Fla., Oct. 26, 2007 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., today announced that the CEOs and executive teams of twenty-one small-cap companies will present at RedChip's Small-Cap Investor Conference in Orlando, Florida, November 3, 2007. The Conference will feature RedChip TV(tm) interviews, networking events, and financial presentations before hundreds of investment bankers, fund managers, institutional and accredited investors, research analysts, and high net worth individuals.
Investors all over the world will be able to see and hear presenters at the conference in real time at http://www.redchip.com. Additionally, investors will have the opportunity to meet one-on-one with the CEOs of presenting companies as well as the RedChip Elite(tm), the Company's top retail brokers, institutional brokers, and fund managers.
The Conference will include presentations from: GeoPharma Inc. (NasdaqCM:GORX - News), Worldwide Manufacturing USA, Inc. (OTC BB:WWMU.OB - News), SpaceDev, Inc. (OTC BB:SPDV.OB - News), Alternative Construction Technologies, Inc. (OTC BB: ACCY.OB), NaturalNano, Inc. (OTC BB:NNAN.OB - News), Ener1, Inc. (OTC BB:ENEI.OB - News), The Amacore Group, Inc. (OTC BB:ACGI.OB - News), Pressure BioSciences, Inc. (NasdaqCM:PBIO - News), Sharps Compliance Corporation (OTC BB:SCOM.OB - News), Advant-e Corporation (OTC BB:AVEE.OB - News), Bridgeline Software, Inc. (NasdaqCM:BLSW - News), Santa Fe Gold Corporation (OTC BB:SFEG.OB - News), BioSolar, Inc (OTC BB:BSRC.OB - News), Carbon Sciences, Inc. (OTC BB:CABN.OB - News), Celsius Holdings, Inc. (OTC BB:CSUH.OB - News), Left Behind Games, Inc. (OTC BB:LFBG.OB - News), Duska Therapeutics, Inc. (OTC BB:DSKA.OB - News), and TMT Capital Corporation (OTC BB:TMTP.OB - News) and Onstream Media Corporation (NasdaqCM:ONSM - News).
The RedChip Conference will feature companies representing the following industries: Biotechnology, Nanotechnology, Environmental Restoration, Diagnostic Substances, Alternative Energy, Communication Equipment, Oil & Gas, Consumer Services, Business Services, Internet Software & Services, Management Services, Specialty Auto Parts, and more.
The conference is free for private investors, fund-managers, retail brokers, and analysts. Space is limited; to register online please visit:
http://www.redchip.com/visibility/conferencePages/Orlando2007/conferenceMain.asp?page=attendees_register&from=OrlandoConf2007Homepage or call 1-800-RedChip (733-2447) ext. 100.
About RedChip Companies, Inc.
RedChip Companies is an international small-cap research and financial public relations firm with offices in Beijing and Orlando and affiliates in New York and San Diego. RedChip delivers measurable results for its clients through its extensive international market expertise as well as its comprehensive platform of products: RedChip Research(tm), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences held throughout the United States, RedChip Radio(tm) and RedChip TV(tm). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/services.asp.
``Discovering Tomorrow's Blue Chips Today.''(tm)
The RedChip Companies Inc. logo is available at
http://www.primenewswire.com/newsroom/prs/?pkgid=2761
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
ITGL New Release
IT Group Holdings, Inc. Invites You to Join Its Investor Update Conference Call on Monday, October 29, 2007, 10:00 a.m. Eastern
Thursday October 25, 2:45 pm ET
LONDON, Oct. 25, 2007 (PRIME NEWSWIRE) -- IT Group Holdings, Inc. (OTC BB: ITGL.OB) announced today that Fred Verkroost, Chairman of IT Group Holdings with his Executive Team will host a conference call on Monday, October 29, 2007 beginning at 10:00 a.m. EDT (7:00 a.m. PDT) to provide an investor update. The call will be open to any interested persons and may contain forward-looking information. What: IT Group Holdings, Inc. Investor Update Conference Call
When: Monday, October 29, 2007 at 10:00 a.m. ET, 7:00 a.m. PT
How: Domestic Dial: 1.866.225.8729
International Dial: 1.480.629.9564
Conference ID: 3799671
Participants are asked to call the assigned number
approximately 10 minutes before the conference call
begins.
To access the live webcast please visit: http://viavid.net/dce.aspx?sid=0000479F
The webcast will be archived after the call and will be available at the original webcast link for thirty days thereafter.
A replay of the conference call will be available two hours after the call and for five business days thereafter (November 5, 2007) by dialing domestically: 800-406-7325 or internationally: 303-590-3030 and entering the following pass code: 3799671.
About IT Group Holdings, Inc.
IT Group Holdings, Inc. trades through its wholly owned UK subsidiary Internet Telecommunications Plc (IT). IT is a provider of telecommunications services in the UK. IT Group Holdings is now established as a carrier-operator supplying resellers (in the UK: service providers) with wholesale access to competitively priced telecommunications lines and high-quality telephone call services including voice, data, value-added services and carrier services such as Voice-over-Internet Protocol (VoIP). IT also offers residential and business subscribers retail access to selected telecommunications services.
Forward-Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on the Company's current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Thursday October 25, 2:45 pm ET
LONDON, Oct. 25, 2007 (PRIME NEWSWIRE) -- IT Group Holdings, Inc. (OTC BB: ITGL.OB) announced today that Fred Verkroost, Chairman of IT Group Holdings with his Executive Team will host a conference call on Monday, October 29, 2007 beginning at 10:00 a.m. EDT (7:00 a.m. PDT) to provide an investor update. The call will be open to any interested persons and may contain forward-looking information. What: IT Group Holdings, Inc. Investor Update Conference Call
When: Monday, October 29, 2007 at 10:00 a.m. ET, 7:00 a.m. PT
How: Domestic Dial: 1.866.225.8729
International Dial: 1.480.629.9564
Conference ID: 3799671
Participants are asked to call the assigned number
approximately 10 minutes before the conference call
begins.
To access the live webcast please visit: http://viavid.net/dce.aspx?sid=0000479F
The webcast will be archived after the call and will be available at the original webcast link for thirty days thereafter.
A replay of the conference call will be available two hours after the call and for five business days thereafter (November 5, 2007) by dialing domestically: 800-406-7325 or internationally: 303-590-3030 and entering the following pass code: 3799671.
About IT Group Holdings, Inc.
IT Group Holdings, Inc. trades through its wholly owned UK subsidiary Internet Telecommunications Plc (IT). IT is a provider of telecommunications services in the UK. IT Group Holdings is now established as a carrier-operator supplying resellers (in the UK: service providers) with wholesale access to competitively priced telecommunications lines and high-quality telephone call services including voice, data, value-added services and carrier services such as Voice-over-Internet Protocol (VoIP). IT also offers residential and business subscribers retail access to selected telecommunications services.
Forward-Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on the Company's current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Thursday, October 25, 2007
BFNH Press Release
BioForce Nanosciences Holdings, Inc. Announces Notice of Allowance for Its Sindex Chip Patent
Thursday October 25, 8:00 am ET
AMES, Iowa, Oct. 25, 2007 (PRIME NEWSWIRE) -- BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH.OB), a company focused on the development and commercialization of nanotech tools and solutions for the life sciences, announced today that it has received Notice of Allowance from the United States Patent Office for Sindex(tm) chips. Sindex(tm) chips are indexed silicon substrates that serve as the basis for a host of ultraminiaturized molecular tests. As an example, BioForce researchers have developed a cancer biomarker screen that requires only four cells using the Sindex(tm) chip. They are the perfect complement to the BioForce Nano eNabler(tm) bench top molecular printer because their indexing system allows users to map the locations of microscopic biological test sites and easily find them for analysis. The Nano eNabler(tm) is being used at elite academic institutions around the world such as Harvard Medical School and Johns Hopkins University for research and development of novel nanotech applications.
Michael Lynch, co-inventor and Product Manager for the Nano eNabler(tm) system said, ``The Nano eNabler creates extremely small features on surfaces for research and development in cell biology, neuroscience, tissue engineering and biosensing. As we make progress in miniaturization of biomedical tests, the capabilities of consumable BioForce products like the Sindex(tm) chip become increasingly important.''
Dr. Juntao Xu, co-inventor, stated, ``We designed Sindex chips to be as simple, yet useful as possible. As research and diagnostics transition from the classical laboratory environment to microscale devices, products like the Sindex(tm) chip will lead to biomedical testing being carried out at your home using a tiny amount of body fluid or just a few, painlessly obtained cells. We at BioForce are striving to be at the forefront of this revolution.''
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences develops and commercializes nanotech tools and solutions for the life sciences. BioForce's flagship product, the Nano eNabler(tm) molecular printer, gives the Company a platform for development and discovery. BioForce technology is being used in sensor functionalization; patterning and cell adhesion; and printing proteins to guide neural cell growth. For more information, visit http://www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Thursday October 25, 8:00 am ET
AMES, Iowa, Oct. 25, 2007 (PRIME NEWSWIRE) -- BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH.OB), a company focused on the development and commercialization of nanotech tools and solutions for the life sciences, announced today that it has received Notice of Allowance from the United States Patent Office for Sindex(tm) chips. Sindex(tm) chips are indexed silicon substrates that serve as the basis for a host of ultraminiaturized molecular tests. As an example, BioForce researchers have developed a cancer biomarker screen that requires only four cells using the Sindex(tm) chip. They are the perfect complement to the BioForce Nano eNabler(tm) bench top molecular printer because their indexing system allows users to map the locations of microscopic biological test sites and easily find them for analysis. The Nano eNabler(tm) is being used at elite academic institutions around the world such as Harvard Medical School and Johns Hopkins University for research and development of novel nanotech applications.
Michael Lynch, co-inventor and Product Manager for the Nano eNabler(tm) system said, ``The Nano eNabler creates extremely small features on surfaces for research and development in cell biology, neuroscience, tissue engineering and biosensing. As we make progress in miniaturization of biomedical tests, the capabilities of consumable BioForce products like the Sindex(tm) chip become increasingly important.''
Dr. Juntao Xu, co-inventor, stated, ``We designed Sindex chips to be as simple, yet useful as possible. As research and diagnostics transition from the classical laboratory environment to microscale devices, products like the Sindex(tm) chip will lead to biomedical testing being carried out at your home using a tiny amount of body fluid or just a few, painlessly obtained cells. We at BioForce are striving to be at the forefront of this revolution.''
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences develops and commercializes nanotech tools and solutions for the life sciences. BioForce's flagship product, the Nano eNabler(tm) molecular printer, gives the Company a platform for development and discovery. BioForce technology is being used in sensor functionalization; patterning and cell adhesion; and printing proteins to guide neural cell growth. For more information, visit http://www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Wednesday, October 24, 2007
OLGX News Alert
Osteologix CEO to Present at Eye for Pharma Early Commercialization, Lifecycle and Portfolio Management Congress 2007
Wednesday October 24, 4:15 pm ET
October 25-26, Barcelo Sants Hotel, Barcelona
SAN FRANCISCO--(BUSINESS WIRE)--Osteologix Inc. (OTC BB: OLGX.OB) today announced that Philip J. Young, President and CEO of Osteologix, will give a presentation entitled, ?Pricing Considerations When Launching a Drug? to over 300 executive delegates at the Eye for Pharma Early Commercialization, Lifecycle and Portfolio Management Congress 2007 on October 25th at the Barcelo Sants Hotel in Barcelona, Spain. The presentation will address the complex issues of drug pricing once a company reaches the Launch stage of commercialization. Young brings to the table over twenty-five years of broad experience with biopharmaceutical development and commercialization. He has been the driving force behind numerous successful drug launches; including Nutropin? (Somatropin [rDNA origin] for injection) and Genotropin?(Somatropin [rDNA origin] for injection), for pediatric growth hormone deficiency, and Corlopam? (Fenoldopam Mesylate Injection, USP) for acute hypertensive episodes.. With a proven track record of success, Mr. Young is leading the development of Osteologix?s principal compound, NB S101, which is currently in Phase II clinical development for the treatment and prevention of osteoporosis. The company is set to release Phase II data in the fourth quarter of 2007.
About NB S101
Osteologix is developing NB S101, a once daily tablet containing strontium malonate, as a treatment for osteoporosis. The phase II study evaluating NB S101 is a randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial with the objective of assessing the effects of NB S101 on bone metabolism while also evaluating its safety, tolerability and pharmacokinetics in postmenopausal women. In addition to the primary endpoint of bone resorption, the company is evaluating the effects of NB S101 on bone formation and bone mineral density.
About Osteoporosis
Osteoporosis is the most common bone disease in humans and, according to the National Osteoporosis Foundation (NOF), 10 million Americans are estimated to have the disease and almost 34 million more are estimated to have osteopenia or low bone mass, placing them at increased risk for osteoporosis. The most severe consequence of osteoporosis is skeletal fracture. Osteoporosis is responsible for more than 1.5 million fractures annually and direct expenditures for hip fractures are estimated to cost society more than $18 billion annually. According to NOF, one in two women and one in four men over age 50 can be expected to have an osteoporosis-related fracture at some time.
About Osteologix
Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. The Company?s vision is to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis. Its lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Wednesday October 24, 4:15 pm ET
October 25-26, Barcelo Sants Hotel, Barcelona
SAN FRANCISCO--(BUSINESS WIRE)--Osteologix Inc. (OTC BB: OLGX.OB) today announced that Philip J. Young, President and CEO of Osteologix, will give a presentation entitled, ?Pricing Considerations When Launching a Drug? to over 300 executive delegates at the Eye for Pharma Early Commercialization, Lifecycle and Portfolio Management Congress 2007 on October 25th at the Barcelo Sants Hotel in Barcelona, Spain. The presentation will address the complex issues of drug pricing once a company reaches the Launch stage of commercialization. Young brings to the table over twenty-five years of broad experience with biopharmaceutical development and commercialization. He has been the driving force behind numerous successful drug launches; including Nutropin? (Somatropin [rDNA origin] for injection) and Genotropin?(Somatropin [rDNA origin] for injection), for pediatric growth hormone deficiency, and Corlopam? (Fenoldopam Mesylate Injection, USP) for acute hypertensive episodes.. With a proven track record of success, Mr. Young is leading the development of Osteologix?s principal compound, NB S101, which is currently in Phase II clinical development for the treatment and prevention of osteoporosis. The company is set to release Phase II data in the fourth quarter of 2007.
About NB S101
Osteologix is developing NB S101, a once daily tablet containing strontium malonate, as a treatment for osteoporosis. The phase II study evaluating NB S101 is a randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial with the objective of assessing the effects of NB S101 on bone metabolism while also evaluating its safety, tolerability and pharmacokinetics in postmenopausal women. In addition to the primary endpoint of bone resorption, the company is evaluating the effects of NB S101 on bone formation and bone mineral density.
About Osteoporosis
Osteoporosis is the most common bone disease in humans and, according to the National Osteoporosis Foundation (NOF), 10 million Americans are estimated to have the disease and almost 34 million more are estimated to have osteopenia or low bone mass, placing them at increased risk for osteoporosis. The most severe consequence of osteoporosis is skeletal fracture. Osteoporosis is responsible for more than 1.5 million fractures annually and direct expenditures for hip fractures are estimated to cost society more than $18 billion annually. According to NOF, one in two women and one in four men over age 50 can be expected to have an osteoporosis-related fracture at some time.
About Osteologix
Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. The Company?s vision is to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis. Its lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
CSUH News Alert
Celsius Holdings Reports Increased Revenue
Wednesday October 24, 3:24 pm ET
DELRAY BEACH, FL--(MARKET WIRE)--Oct 24, 2007 -- Celsius Holdings, Inc. (the "Company") (OTC BB: CSUH.OB) today reported revenue for the three month period ended September 30, 2007 was $508,000 as compared to $376,000 for the prior quarter, the three month period ended June 30, 2007 and as compared to $414,000 for the three month period ended September 30, 2006. The Company also reported a net loss of $784,000 or $0.01 per basic and diluted share for the three months ended September 30, 2007. This compares with net loss of $418,000 or $0.01 per basic and diluted share for the three months ended September 30, 2006.
Mr. Stephen C. Haley, chairman and CEO, said: "We are pleased to announce that we are seeing much more activity around our brand and have been successful in placing Celsius in many new retailers during the last few months. The revenue included more high profile retailers as well as significant reorders from multiple channels, grocery, convenience and health & fitness. The increase was not huge yet but the 'quality' of the revenue was high."
"Operationally," Mr. Haley said, "with our growing sales force and distribution coverage, our revenue is becoming more predictable. With this we have been able to get our gross margin back up to close to where we believe it should be. With more revenue, better forecasts and better purchasing leverage our gross profit was over 47% in the quarter."
Mr. Haley continued by stating, "We are pleased that the registration statement required under our stock purchase agreement with Fusion Capital has been declared effective by the Securities and Exchange Commission and we have started to get our financing from this source. Since October 16 we have sold Fusion Capital shares totaling $300,000. This will give us the possibility to more actively market our products and should show positive results to our revenue growth."
The company's quarterly conference call is scheduled for 4:30 p.m. ET, Thursday October 25, 2007. The call may be accessed through live webcast links on the company's Internet home page, www.celsius.com. The webcast will be archived and available on the company's website for one month following the call.
About Celsius Holdings, Inc.
Celsius Holdings, Inc. (OTC BB: CSUH.OB) manufactures Celsius through its wholly owned operating subsidiary, Celsius, Inc. Celsius, Inc. is quickly gaining attention in the emerging $36 billion functional food and beverage industry, as the creator of the calorie burning beverage category and as a pioneer and leader in developing healthier beverage choices. Celsius, Inc. is building unique distribution strategies to gain broad penetration in all channels serving its consumer targets. The continued mission of Celsius, Inc. is to create healthy refreshment through science and innovation and growth through passion and integrity. For more information about Celsius and Celsius, Inc., please visit http://www.celsius.com. For investor information, please visit http://www.redchip.com.
Forward-Looking Statements
This press release may contain statements, which are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements contain projections of the Company's future results of operations, financial position or state other forward-looking information. In some cases you can identify these statements by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will," and "would" or similar words. You should not rely on forward-looking statements because the Company's actual results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: general economic and business conditions; our business strategy for expanding our presence in our industry; anticipated trends in our financial condition and results of operation; the impact of competition and technology change; existing and future regulations effecting our business, and other risks and uncertainties discussed in reports the Company files from time to time with the Securities and Exchange Commission. The Company does not intend to and undertakes no duty to update the information contained in this press release.
Wednesday October 24, 3:24 pm ET
DELRAY BEACH, FL--(MARKET WIRE)--Oct 24, 2007 -- Celsius Holdings, Inc. (the "Company") (OTC BB: CSUH.OB) today reported revenue for the three month period ended September 30, 2007 was $508,000 as compared to $376,000 for the prior quarter, the three month period ended June 30, 2007 and as compared to $414,000 for the three month period ended September 30, 2006. The Company also reported a net loss of $784,000 or $0.01 per basic and diluted share for the three months ended September 30, 2007. This compares with net loss of $418,000 or $0.01 per basic and diluted share for the three months ended September 30, 2006.
Mr. Stephen C. Haley, chairman and CEO, said: "We are pleased to announce that we are seeing much more activity around our brand and have been successful in placing Celsius in many new retailers during the last few months. The revenue included more high profile retailers as well as significant reorders from multiple channels, grocery, convenience and health & fitness. The increase was not huge yet but the 'quality' of the revenue was high."
"Operationally," Mr. Haley said, "with our growing sales force and distribution coverage, our revenue is becoming more predictable. With this we have been able to get our gross margin back up to close to where we believe it should be. With more revenue, better forecasts and better purchasing leverage our gross profit was over 47% in the quarter."
Mr. Haley continued by stating, "We are pleased that the registration statement required under our stock purchase agreement with Fusion Capital has been declared effective by the Securities and Exchange Commission and we have started to get our financing from this source. Since October 16 we have sold Fusion Capital shares totaling $300,000. This will give us the possibility to more actively market our products and should show positive results to our revenue growth."
The company's quarterly conference call is scheduled for 4:30 p.m. ET, Thursday October 25, 2007. The call may be accessed through live webcast links on the company's Internet home page, www.celsius.com. The webcast will be archived and available on the company's website for one month following the call.
About Celsius Holdings, Inc.
Celsius Holdings, Inc. (OTC BB: CSUH.OB) manufactures Celsius through its wholly owned operating subsidiary, Celsius, Inc. Celsius, Inc. is quickly gaining attention in the emerging $36 billion functional food and beverage industry, as the creator of the calorie burning beverage category and as a pioneer and leader in developing healthier beverage choices. Celsius, Inc. is building unique distribution strategies to gain broad penetration in all channels serving its consumer targets. The continued mission of Celsius, Inc. is to create healthy refreshment through science and innovation and growth through passion and integrity. For more information about Celsius and Celsius, Inc., please visit http://www.celsius.com. For investor information, please visit http://www.redchip.com.
Forward-Looking Statements
This press release may contain statements, which are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements contain projections of the Company's future results of operations, financial position or state other forward-looking information. In some cases you can identify these statements by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will," and "would" or similar words. You should not rely on forward-looking statements because the Company's actual results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: general economic and business conditions; our business strategy for expanding our presence in our industry; anticipated trends in our financial condition and results of operation; the impact of competition and technology change; existing and future regulations effecting our business, and other risks and uncertainties discussed in reports the Company files from time to time with the Securities and Exchange Commission. The Company does not intend to and undertakes no duty to update the information contained in this press release.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
ITGL News Alert
IT Group Holdings, Inc. Maintains British Telecom Contract and Builds Competitive Advantage
Wednesday October 24, 2:11 pm ET
New Business Plan Developed
LONDON, Oct. 24, 2007 (PRIME NEWSWIRE) -- IT Group Holdings, Inc. (OTC BB: ITGL.OB) announced today that its operating entity, Internet Telecommunications Plc (``ITPLC'') will maintain its wholesale line rental agreement with British Telecom, which will continue to give the company an important competitive advantage as the company secures new contracts and strengthens existing relationships.
The Board of Directors has appointed an acting CEO and Commercial Director to continue to drive its Reseller business. Commenting on this development, Guy K. Stewart, Jr., a director of Internet Telecommunications Plc, said, ``We have been able to secure many of our previous customers even as we have undergone executive level management changes. We are very pleased that we continue to have in place a powerful Telecom Switch with a capacity to handle over 500 million minutes of telecommunications traffic every month. With this Switch in place, we have the network capacity to generate approximately $500 million in revenues without the need for major new capital investments.''
With the new business plan in place, the Company will now focus on capturing the first 2-3% of the UK market to deliver a solid base of recurring revenues and profitability. As the telecommunications market is an 'additive' market, the growth in revenues will be quickly attained from new subscribers. Commenting on this, Dr. Fredrik Verkroost, Chairman of IT Group Holdings, Inc. said, ``We are in a similar phase to filling hotel rooms in a large new hotel. Our switch is in operation and can now be filled with traffic from Service Providers on longer-term contracts. These Service Providers in turn can bring large numbers of their existing subscribers onto our network, which considerably simplifies our marketing approach. We can continue to offer significant savings to our Resellers. We are very confident in our ability to shore up our existing customer base and bring in new business.''
About IT Group Holdings, Inc.
IT Group Holdings, Inc. trades through its wholly owned UK subsidiary Internet Telecommunications Plc (IT). IT is a provider of telecommunications services in the UK. IT Group Holdings is now established as a carrier-operator supplying resellers (in the UK: service providers) with wholesale access to competitively priced telecommunications lines and high-quality telephone call services including voice, data, value-added services and carrier services such as Voice-over-Internet Protocol (VoIP). IT also offers residential and business subscribers retail access to selected telecommunications services.
Forward-Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on the Company's current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Wednesday October 24, 2:11 pm ET
New Business Plan Developed
LONDON, Oct. 24, 2007 (PRIME NEWSWIRE) -- IT Group Holdings, Inc. (OTC BB: ITGL.OB) announced today that its operating entity, Internet Telecommunications Plc (``ITPLC'') will maintain its wholesale line rental agreement with British Telecom, which will continue to give the company an important competitive advantage as the company secures new contracts and strengthens existing relationships.
The Board of Directors has appointed an acting CEO and Commercial Director to continue to drive its Reseller business. Commenting on this development, Guy K. Stewart, Jr., a director of Internet Telecommunications Plc, said, ``We have been able to secure many of our previous customers even as we have undergone executive level management changes. We are very pleased that we continue to have in place a powerful Telecom Switch with a capacity to handle over 500 million minutes of telecommunications traffic every month. With this Switch in place, we have the network capacity to generate approximately $500 million in revenues without the need for major new capital investments.''
With the new business plan in place, the Company will now focus on capturing the first 2-3% of the UK market to deliver a solid base of recurring revenues and profitability. As the telecommunications market is an 'additive' market, the growth in revenues will be quickly attained from new subscribers. Commenting on this, Dr. Fredrik Verkroost, Chairman of IT Group Holdings, Inc. said, ``We are in a similar phase to filling hotel rooms in a large new hotel. Our switch is in operation and can now be filled with traffic from Service Providers on longer-term contracts. These Service Providers in turn can bring large numbers of their existing subscribers onto our network, which considerably simplifies our marketing approach. We can continue to offer significant savings to our Resellers. We are very confident in our ability to shore up our existing customer base and bring in new business.''
About IT Group Holdings, Inc.
IT Group Holdings, Inc. trades through its wholly owned UK subsidiary Internet Telecommunications Plc (IT). IT is a provider of telecommunications services in the UK. IT Group Holdings is now established as a carrier-operator supplying resellers (in the UK: service providers) with wholesale access to competitively priced telecommunications lines and high-quality telephone call services including voice, data, value-added services and carrier services such as Voice-over-Internet Protocol (VoIP). IT also offers residential and business subscribers retail access to selected telecommunications services.
Forward-Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on the Company's current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
GWBC News Alert
Butte Creek Brewing Company -- The Official Beer of Planet Earth(TM) -- Featured Today at Two Prestigious Events
Wednesday October 24, 11:35 am ET
BOULDER, Colo.--(BUSINESS WIRE)--Golden West Brewing Company (OTC BB: GWBC.OB) is pleased to announce its line of organic ales and lagers will be showcased at tastings today at two renowned California events:
The 17th Annual Environmental Media Awards honor film and television productions and individuals who increase public awareness of environmental issues while inspiring personal action on these issues. The awards recognize writers, producers, directors, actors, and other individuals in the entertainment industry actively expressing their concern for the environment through their work. The star-studded EMA award show will air worldwide on November 7th on E! Entertainment Television and BBC International.
In San Francisco, Business for Social Responsibility (BSR) will host 1,100 leaders from 40 countries in San Francisco, Calif., this week at its global conference, the most influential world event dedicated to corporate responsibility and sustainable business strategies.
"These types of events are great exposure for our Butte Creek organic ales and lagers, as they mirror our corporate philosophy," said John Power, President of Golden West Brewing.
About Golden West Brewing Company, Inc.: Golden West Brewing Company, Inc. was formed in 2003 and completed a small self-underwritten public offering in 2006. Golden West, through its wholly owned subsidiary Golden West Brewing Company, acquired the assets and certain liabilities of Butte Creek Brewing Company of Chico, California, in August 2005. Founded in 1996, Butte Creek Brewing Company is one of the pioneer certified organic micro-breweries in the United States. Butte Creek?s Organic Pilsner won a Gold Medal at the 2006 Great American Brewers Festival (GABF).
This press release may contain projection and other forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. Any such projections or statement reflect the company?s current views with respect to future events and financial performance. No assurances can be given, however, that these events will occur or that such projections will be achieved and that actual results could differ materially from those projected. A discussion of important factors that could cause actual results to differ from those projected is included in the company?s periodic reports filed with the Securities and Exchange Commission (at www.sec.gov).
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Wednesday October 24, 11:35 am ET
BOULDER, Colo.--(BUSINESS WIRE)--Golden West Brewing Company (OTC BB: GWBC.OB) is pleased to announce its line of organic ales and lagers will be showcased at tastings today at two renowned California events:
The 17th Annual Environmental Media Awards honor film and television productions and individuals who increase public awareness of environmental issues while inspiring personal action on these issues. The awards recognize writers, producers, directors, actors, and other individuals in the entertainment industry actively expressing their concern for the environment through their work. The star-studded EMA award show will air worldwide on November 7th on E! Entertainment Television and BBC International.
In San Francisco, Business for Social Responsibility (BSR) will host 1,100 leaders from 40 countries in San Francisco, Calif., this week at its global conference, the most influential world event dedicated to corporate responsibility and sustainable business strategies.
"These types of events are great exposure for our Butte Creek organic ales and lagers, as they mirror our corporate philosophy," said John Power, President of Golden West Brewing.
About Golden West Brewing Company, Inc.: Golden West Brewing Company, Inc. was formed in 2003 and completed a small self-underwritten public offering in 2006. Golden West, through its wholly owned subsidiary Golden West Brewing Company, acquired the assets and certain liabilities of Butte Creek Brewing Company of Chico, California, in August 2005. Founded in 1996, Butte Creek Brewing Company is one of the pioneer certified organic micro-breweries in the United States. Butte Creek?s Organic Pilsner won a Gold Medal at the 2006 Great American Brewers Festival (GABF).
This press release may contain projection and other forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. Any such projections or statement reflect the company?s current views with respect to future events and financial performance. No assurances can be given, however, that these events will occur or that such projections will be achieved and that actual results could differ materially from those projected. A discussion of important factors that could cause actual results to differ from those projected is included in the company?s periodic reports filed with the Securities and Exchange Commission (at www.sec.gov).
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
BSRC Press Release
Component Suppliers Shine Brightly Amid Profit Pressure in Solar Power Industry
Wednesday October 24, 9:05 am ET
BioSolar Anticipates Benefit From Recent Announcements by Major Photovoltaic Manufacturers
SANTA CLARITA, CA--(MARKET WIRE)--Oct 24, 2007 -- BioSolar(TM), Inc. (OTC BB: BSRC.OB), developer of a breakthrough technology to produce bioplastic materials from renewable plant sources that will reduce the cost of solar cells, had upbeat comments regarding recent news that the industry's major manufacturers of solar cells are projecting lowered profit margins on completed solar cells. As noted in the Associated Press' Sector Snap: Solar Power Industry, Friday, October 19, 2007, this squeeze on the companies' profits is being triggered by a tightness in supply of polysilicon (the key component in photovoltaic solar cells), coupled with surging demand for the finished photovoltaic cells. This creates a growth opportunity for companies like BioSolar that can provide the photovoltaic cell manufacturers with a substantial cost cutting solution.
The combination of decreasing supply and increasing demand, while creating a profit squeeze for the manufacturers of completed solar cells, creates an urgent and sizable sales opportunity for those suppliers of the other components in a solar cell that allow the manufacturers to decrease the cost of the various components that make up the completed photovoltaic cell. Adding further pricing pressure to the manufacturers, the price of crude oil reached an all time high, topping $90 per barrel during Friday's trading.
"BioSolar has developed a bio-based plastic material for the backsheet component of the solar cell that represents a huge cost saving -- indications are that it's as much 50% savings over the current pricing of petroleum based plastics currently being used," said Dr. David Lee, BioSolar's CEO. "We are seeing this combination of factors in the industry drive the cell manufacturers to be much more creative as they seek out other ways of reducing the overall cost of the finished product."
"Current and ongoing tests and discussions with our existing strategic partners in the industry are proceeding as anticipated," said BioSolar's CTO, Dr. Stan Levy. "Based on recent discussions with newly interested parties, we are anticipating rapid market penetration as our bio-based backsheet product gains Underwriter's Laboratory(TM) approval and our prototype life cycle testing completes its course and we move into commercial sales mode."
About BioSolar, Inc.
BioSolar, Inc. is developing a breakthrough technology to produce bioplastic materials from renewable plant sources that will reduce the cost per watt of solar cells. Most of the solar industry is focused on photovoltaic efficiency to reduce cost. BioSolar is the first company to introduce a new dimension of cost reduction by replacing petroleum-based plastic solar cell components with durable bio-based plastics. To learn more about BioSolar, please visit our website at http://www.biosolar.com.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Wednesday October 24, 9:05 am ET
BioSolar Anticipates Benefit From Recent Announcements by Major Photovoltaic Manufacturers
SANTA CLARITA, CA--(MARKET WIRE)--Oct 24, 2007 -- BioSolar(TM), Inc. (OTC BB: BSRC.OB), developer of a breakthrough technology to produce bioplastic materials from renewable plant sources that will reduce the cost of solar cells, had upbeat comments regarding recent news that the industry's major manufacturers of solar cells are projecting lowered profit margins on completed solar cells. As noted in the Associated Press' Sector Snap: Solar Power Industry, Friday, October 19, 2007, this squeeze on the companies' profits is being triggered by a tightness in supply of polysilicon (the key component in photovoltaic solar cells), coupled with surging demand for the finished photovoltaic cells. This creates a growth opportunity for companies like BioSolar that can provide the photovoltaic cell manufacturers with a substantial cost cutting solution.
The combination of decreasing supply and increasing demand, while creating a profit squeeze for the manufacturers of completed solar cells, creates an urgent and sizable sales opportunity for those suppliers of the other components in a solar cell that allow the manufacturers to decrease the cost of the various components that make up the completed photovoltaic cell. Adding further pricing pressure to the manufacturers, the price of crude oil reached an all time high, topping $90 per barrel during Friday's trading.
"BioSolar has developed a bio-based plastic material for the backsheet component of the solar cell that represents a huge cost saving -- indications are that it's as much 50% savings over the current pricing of petroleum based plastics currently being used," said Dr. David Lee, BioSolar's CEO. "We are seeing this combination of factors in the industry drive the cell manufacturers to be much more creative as they seek out other ways of reducing the overall cost of the finished product."
"Current and ongoing tests and discussions with our existing strategic partners in the industry are proceeding as anticipated," said BioSolar's CTO, Dr. Stan Levy. "Based on recent discussions with newly interested parties, we are anticipating rapid market penetration as our bio-based backsheet product gains Underwriter's Laboratory(TM) approval and our prototype life cycle testing completes its course and we move into commercial sales mode."
About BioSolar, Inc.
BioSolar, Inc. is developing a breakthrough technology to produce bioplastic materials from renewable plant sources that will reduce the cost per watt of solar cells. Most of the solar industry is focused on photovoltaic efficiency to reduce cost. BioSolar is the first company to introduce a new dimension of cost reduction by replacing petroleum-based plastic solar cell components with durable bio-based plastics. To learn more about BioSolar, please visit our website at http://www.biosolar.com.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
GWPC News Alert
Gulf Western Petroleum Announces Drilling of Fourth Frio Well In Texas Shamrock Project
Wednesday October 24, 1:00 am ET
HOUSTON, Oct. 24 /PRNewswire-FirstCall/ - Gulf Western Petroleum Corporation ("Gulf Western") (OTCBB: GWPC/Frankfurt: GER), is pleased to announce they have been advised by the Operator that the drilling rig is on location at the Red Breast # 1 drill site, and that the Red Breast # 1 will spud today. After obtaining the log results from the first three wells, Gulf Western increased its position in the Shamrock Project in Dewitt County Texas by two additional wells, bringing their current participation in the Shamrock Project to five wells. The two additional wells are the Red Breast # 1 and the Michael Collins # 1. Both wells will target the same formation as the first three Frio prospects, the Jameson Sand at 3200'.
The Shamrock Project is a five well Frio-age prospect identified through 3-D seismic. Gulf Western currently has three wells drilled and completed. The wells are the Polinard-Lee # 1 well; the Miller-Thomas # 1 well; and the Bushmill # 1 well. All three wells flow tested in excess of 300 Mcfd and are awaiting hook up to the sales line.
Frio-age wells have proven to be prolific natural gas producers throughout the Texas Gulf Coast region. Typical Frio wells produce at approximately 200 to 300 Mcf per day with estimated total recoverable reserves of approximately 500 million cubic feet to 1 Billion cubic feet.
This press release may include forward-looking statements based on the Company's current expectations as to future events. The forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. For example, the extraction and sale of natural gas from the wells involves a number of costs and risks, which may limit our ability to generate cash flow from the wells. In addition, the business of Gulf Western Petroleum Corporation is subject to a number of risks typical of an oil and gas exploration and development company including, among other things, the inherent uncertainties associated with oil and gas exploration; laws, environmental, judicial, regulatory, political and competitive developments in areas in which Gulf Western Petroleum Corporation operates; and technological, mechanical and operational difficulties encountered in connection with Gulf Western Petroleum Corporation's activities.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Wednesday October 24, 1:00 am ET
HOUSTON, Oct. 24 /PRNewswire-FirstCall/ - Gulf Western Petroleum Corporation ("Gulf Western") (OTCBB: GWPC/Frankfurt: GER), is pleased to announce they have been advised by the Operator that the drilling rig is on location at the Red Breast # 1 drill site, and that the Red Breast # 1 will spud today. After obtaining the log results from the first three wells, Gulf Western increased its position in the Shamrock Project in Dewitt County Texas by two additional wells, bringing their current participation in the Shamrock Project to five wells. The two additional wells are the Red Breast # 1 and the Michael Collins # 1. Both wells will target the same formation as the first three Frio prospects, the Jameson Sand at 3200'.
The Shamrock Project is a five well Frio-age prospect identified through 3-D seismic. Gulf Western currently has three wells drilled and completed. The wells are the Polinard-Lee # 1 well; the Miller-Thomas # 1 well; and the Bushmill # 1 well. All three wells flow tested in excess of 300 Mcfd and are awaiting hook up to the sales line.
Frio-age wells have proven to be prolific natural gas producers throughout the Texas Gulf Coast region. Typical Frio wells produce at approximately 200 to 300 Mcf per day with estimated total recoverable reserves of approximately 500 million cubic feet to 1 Billion cubic feet.
This press release may include forward-looking statements based on the Company's current expectations as to future events. The forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. For example, the extraction and sale of natural gas from the wells involves a number of costs and risks, which may limit our ability to generate cash flow from the wells. In addition, the business of Gulf Western Petroleum Corporation is subject to a number of risks typical of an oil and gas exploration and development company including, among other things, the inherent uncertainties associated with oil and gas exploration; laws, environmental, judicial, regulatory, political and competitive developments in areas in which Gulf Western Petroleum Corporation operates; and technological, mechanical and operational difficulties encountered in connection with Gulf Western Petroleum Corporation's activities.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
ACCY News Alert
Alternative Construction Technologies Expands Sales and Marketing Reach by Adding 30 Manufacturers' Representatives
Tuesday October 23, 3:13 pm ET
Eco-$mart Signs Exclusive Structural Insulated Panel Marketing Contract With Alternative Construction Technologies
MELBOURNE, Fla., Oct. 23, 2007 (PRIME NEWSWIRE) -- Alternative Construction Technologies, Inc. (OTC BB: ACCY.OB) announced today that it has signed an exclusive sales and marketing contract with Eco-$mart, Inc., a 14-year-old distributor of energy efficient, socially responsible, sustainable and environmentally friendly building materials and products used throughout all facets of construction. Alternative Construction Technologies announced this monumental agreement from New York City in connection with its meetings at the United Nations during the historic U.N. Day. Under the agreement, Eco-$mart will not provide any other structural insulated panel product.
The contract will provide Alternative Construction Technologies with representation by 30 veteran environmentally conscious sales agents and Earth Stewards located in Florida, Georgia, North Carolina, South Carolina, Louisiana and Texas. These are ideally suited markets for Alternative Construction Technologies' products and services. Eco-$mart will include Alternative Construction Technologies' ACTech Panel System and pre-engineered designs on its well accessed B2B and B2C website. Conversely, Eco-$mart will gain: access to a state-of-the-art structural insulated panel system from a vertically integrated company that offers ``off the shelf plans''; architectural and design services for custom construction applications; development and construction consulting services; manufacturing access to a patented, proprietary construction technology; construction and contracting services; and a strong reputation based upon third party product testing with a myriad of certifications.
Matt Ross, the President and Founder of Eco-$mart stated, ``We have been evaluating green structural systems for over 14 years and promoting the best of them to builders in Florida, the Gulf States and the Southeastern region. The Actech panel system is the most complete, fastest, healthiest, most energy efficient, and most economical structural system on the market. We are thrilled to be a part of the sales team for such an exciting product and fast growing company and expect sales to ramp up vigorously. Achieving up to 70% monthly energy savings and disaster resistant strength with a Class-1 fire rating will only add to consumer interest.''
``Back when our companies started our endeavors, it was a difficult and challenging business environment for e-friendly companies,'' stated A.J. Francel, the COO of Alternative Construction Technologies, ``but now the pendulum has swung in the other direction for us. Things like: the visionary efforts of the United Nations Environment Programme (UNEP); Al Gore winning a Nobel Prize for his climate work; the Department of Energy mandating affordable zero energy homes within 12 years; Executive Orders issued by several state Governors; major business realignments like British Petroleum (NYSE:BP - News) switching from fossil fuels to solar energy; and the persistent rise of energy consumption and costs are all placing companies like ours in the limelight. We feel that Eco-Smart is a perfect compliment and a great partner as this industry emerges onto center-stage.''
The agreement calls for sales efforts to commence immediately.
Alternative Construction Technologies, Inc. (ACT) possesses a unique and patented construction technology called the ACTech(r) Panel System that is used in the design and production of state of the art buildings in commercial, residential, industrial and modular building applications. Generically known as structural insulated panels (SIPs), ACT's revolutionary and efficient construction solution utilizes an inherently better galvanized steel ``skin'' SIP system to complete energy efficient, stronger, safer, faster, and more economical structure than conventional wood and brick based building products. The patented ACTech(r) Panel is environmentally-friendly and easier to construct with -- not only saving labor cost and cutting construction time, but also reducing recurring monthly heating and cooling energy bills by 30-50% and often more. Most importantly, the ACTech(r) Panel possesses disaster resistant strength and has tested stronger than conventional concrete block or wood frame construction. In hurricane projectile tests, the ACTech(r) Panel continues to meet the most stringent wind, projectile and uplift codes in the nation levied by the 2006 Florida Building Code. The ACTech(r) Panel System offers builders and consumers many competitive and comparative advantages of use due to its wide range of attributes. As this new construction technology gains awareness, or hurricane and tornado-prone states establish new building codes and rebuild from recent weather disasters, ACT believes its' products will be in greater demand. ACT has recently added complementary services including design, consulting, and construction through its various general contracting companies located in Florida, Georgia and Tennessee.
Eco-$mart, Inc. is a National distributor of energy and resource efficient construction materials. Each material represented is approved by the non-profit Florida House Institute for Sustainable Development (http://www.I4SD.org), located in Sarasota, Florida. Eco-$mart is also involved in the design and construction of a wide range of environmental demonstration projects around the state of Florida, and has inspired many conventional builders and architects to include sustainable construction features in their projects, winning some state wide energy efficiency awards. Eco-$mart, Inc. is also an EPA ENERGY STAR Homes and Buildings Partner, and is an active member in the Florida Green Building Coalition, a group developing sustainable home, building, development and community standards for Florida (http://www.floridagreenbuilding.org). To learn more, please visit Eco-$mart, Inc. on the web at http://www.eco-smart.com.This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products, which we may not produce today and that meet defined specifications. When used in this press release, the words ``plan,'' ``expect,'' ``believe,'' and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Tuesday October 23, 3:13 pm ET
Eco-$mart Signs Exclusive Structural Insulated Panel Marketing Contract With Alternative Construction Technologies
MELBOURNE, Fla., Oct. 23, 2007 (PRIME NEWSWIRE) -- Alternative Construction Technologies, Inc. (OTC BB: ACCY.OB) announced today that it has signed an exclusive sales and marketing contract with Eco-$mart, Inc., a 14-year-old distributor of energy efficient, socially responsible, sustainable and environmentally friendly building materials and products used throughout all facets of construction. Alternative Construction Technologies announced this monumental agreement from New York City in connection with its meetings at the United Nations during the historic U.N. Day. Under the agreement, Eco-$mart will not provide any other structural insulated panel product.
The contract will provide Alternative Construction Technologies with representation by 30 veteran environmentally conscious sales agents and Earth Stewards located in Florida, Georgia, North Carolina, South Carolina, Louisiana and Texas. These are ideally suited markets for Alternative Construction Technologies' products and services. Eco-$mart will include Alternative Construction Technologies' ACTech Panel System and pre-engineered designs on its well accessed B2B and B2C website. Conversely, Eco-$mart will gain: access to a state-of-the-art structural insulated panel system from a vertically integrated company that offers ``off the shelf plans''; architectural and design services for custom construction applications; development and construction consulting services; manufacturing access to a patented, proprietary construction technology; construction and contracting services; and a strong reputation based upon third party product testing with a myriad of certifications.
Matt Ross, the President and Founder of Eco-$mart stated, ``We have been evaluating green structural systems for over 14 years and promoting the best of them to builders in Florida, the Gulf States and the Southeastern region. The Actech panel system is the most complete, fastest, healthiest, most energy efficient, and most economical structural system on the market. We are thrilled to be a part of the sales team for such an exciting product and fast growing company and expect sales to ramp up vigorously. Achieving up to 70% monthly energy savings and disaster resistant strength with a Class-1 fire rating will only add to consumer interest.''
``Back when our companies started our endeavors, it was a difficult and challenging business environment for e-friendly companies,'' stated A.J. Francel, the COO of Alternative Construction Technologies, ``but now the pendulum has swung in the other direction for us. Things like: the visionary efforts of the United Nations Environment Programme (UNEP); Al Gore winning a Nobel Prize for his climate work; the Department of Energy mandating affordable zero energy homes within 12 years; Executive Orders issued by several state Governors; major business realignments like British Petroleum (NYSE:BP - News) switching from fossil fuels to solar energy; and the persistent rise of energy consumption and costs are all placing companies like ours in the limelight. We feel that Eco-Smart is a perfect compliment and a great partner as this industry emerges onto center-stage.''
The agreement calls for sales efforts to commence immediately.
Alternative Construction Technologies, Inc. (ACT) possesses a unique and patented construction technology called the ACTech(r) Panel System that is used in the design and production of state of the art buildings in commercial, residential, industrial and modular building applications. Generically known as structural insulated panels (SIPs), ACT's revolutionary and efficient construction solution utilizes an inherently better galvanized steel ``skin'' SIP system to complete energy efficient, stronger, safer, faster, and more economical structure than conventional wood and brick based building products. The patented ACTech(r) Panel is environmentally-friendly and easier to construct with -- not only saving labor cost and cutting construction time, but also reducing recurring monthly heating and cooling energy bills by 30-50% and often more. Most importantly, the ACTech(r) Panel possesses disaster resistant strength and has tested stronger than conventional concrete block or wood frame construction. In hurricane projectile tests, the ACTech(r) Panel continues to meet the most stringent wind, projectile and uplift codes in the nation levied by the 2006 Florida Building Code. The ACTech(r) Panel System offers builders and consumers many competitive and comparative advantages of use due to its wide range of attributes. As this new construction technology gains awareness, or hurricane and tornado-prone states establish new building codes and rebuild from recent weather disasters, ACT believes its' products will be in greater demand. ACT has recently added complementary services including design, consulting, and construction through its various general contracting companies located in Florida, Georgia and Tennessee.
Eco-$mart, Inc. is a National distributor of energy and resource efficient construction materials. Each material represented is approved by the non-profit Florida House Institute for Sustainable Development (http://www.I4SD.org), located in Sarasota, Florida. Eco-$mart is also involved in the design and construction of a wide range of environmental demonstration projects around the state of Florida, and has inspired many conventional builders and architects to include sustainable construction features in their projects, winning some state wide energy efficiency awards. Eco-$mart, Inc. is also an EPA ENERGY STAR Homes and Buildings Partner, and is an active member in the Florida Green Building Coalition, a group developing sustainable home, building, development and community standards for Florida (http://www.floridagreenbuilding.org). To learn more, please visit Eco-$mart, Inc. on the web at http://www.eco-smart.com.This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products, which we may not produce today and that meet defined specifications. When used in this press release, the words ``plan,'' ``expect,'' ``believe,'' and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
CSUH Press Release
Celsius Holdings, Inc. Invites You to Join Its Third Quarter Financial Results Conference Call On Thursday, October 25, 2007, At 4:30 p.m. Eastern
Tuesday October 23, 11:48 am ET
DELRAY BEACH, Fla., Oct. 23, 2007 (PRIME NEWSWIRE) -- Celsius Holdings, Inc. (OTC BB: CSUH.OB), maker of Celsius(r), the first healthy, calorie burning beverage that delivers sustained energy and great taste, based on trusted science, announced today that it will host a conference call on Thursday, October 25, 2007 beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to review third quarter financial results. The call will be open to any interested persons and may contain forward-looking information.
What: Celsius Holdings, Inc. Third Quarter Financial Results
When: Thursday, October 25, 2007 at 4:30 p.m. ET, 1:30 p.m. PT
How: Webcast http://www.celsius.com
Domestic Dial: 1.866.225.8754
International Dial: 1.480.629.9562
Conference ID: 3798686
Participants are asked to call the assigned number
approximately 5 minutes before the conference call begins.
To access the live webcast please visit: http://www.celsius.com
The webcast will be archived after the call and will be available at the original webcast link for thirty days thereafter.
A replay of the conference call will be available two hours after the call and for five business days thereafter (November 1, 2007) by dialing domestically: 800-406-7325 or internationally: 303-590-3030 and entering the following pass code: 3798686.
About Celsius Holdings, Inc.
Celsius Holdings, Inc. (OTC BB: CSUH.OB) manufactures Celsius through its wholly-owned operating subsidiary, Celsius, Inc. Celsius Inc. is quickly gaining attention in the emerging $36 billion functional food and beverage industry, as the creator of the calorie burning beverage category and as a pioneer and leader in developing healthier beverage choices. Celsius, Inc. is building unique distribution strategies to gain broad penetration in all channels serving its consumer targets in all geographies. The continued mission of Celsius, Inc. is to create healthy refreshment through science and innovation and growth through passion and integrity. For more information about Celsius and Celsius, Inc., please visit http://www.celsius.com. For investor information, please visit http://www.redchip.com.
Forward-Looking Statements
This press release may contain statements, which are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements contain projections of Celsius Holdings' future results of operations, financial position or state other forward-looking information. In some cases you can identify these statements by forward-looking words such as ``anticipate,'' ``believe,'' ``could,'' ``estimate,'' ``expect,'' ``intend,'' ``may,'' ``should,'' ``will,'' and ``would'' or similar words. You should not rely on forward-looking statements because Celsius Holdings' actual results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: our business strategy for expanding our presence in our industry; anticipated trends in our financial condition and results of operation; the impact of competition and technology change; existing and future regulations effecting our business, and changes in general economic conditions in the markets in which we may compete. For further details and a discussion of these and other risks and uncertainties, see our periodic reports including current reports on Form 8-K, quarterly reports on Form 10-QSB and our annual report on Form 10-KSB, furnished to and filed with the Securities and Exchange Commission. Celsius Holdings does not intend to and undertakes no duty to update the information contained in this press release.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Tuesday October 23, 11:48 am ET
DELRAY BEACH, Fla., Oct. 23, 2007 (PRIME NEWSWIRE) -- Celsius Holdings, Inc. (OTC BB: CSUH.OB), maker of Celsius(r), the first healthy, calorie burning beverage that delivers sustained energy and great taste, based on trusted science, announced today that it will host a conference call on Thursday, October 25, 2007 beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to review third quarter financial results. The call will be open to any interested persons and may contain forward-looking information.
What: Celsius Holdings, Inc. Third Quarter Financial Results
When: Thursday, October 25, 2007 at 4:30 p.m. ET, 1:30 p.m. PT
How: Webcast http://www.celsius.com
Domestic Dial: 1.866.225.8754
International Dial: 1.480.629.9562
Conference ID: 3798686
Participants are asked to call the assigned number
approximately 5 minutes before the conference call begins.
To access the live webcast please visit: http://www.celsius.com
The webcast will be archived after the call and will be available at the original webcast link for thirty days thereafter.
A replay of the conference call will be available two hours after the call and for five business days thereafter (November 1, 2007) by dialing domestically: 800-406-7325 or internationally: 303-590-3030 and entering the following pass code: 3798686.
About Celsius Holdings, Inc.
Celsius Holdings, Inc. (OTC BB: CSUH.OB) manufactures Celsius through its wholly-owned operating subsidiary, Celsius, Inc. Celsius Inc. is quickly gaining attention in the emerging $36 billion functional food and beverage industry, as the creator of the calorie burning beverage category and as a pioneer and leader in developing healthier beverage choices. Celsius, Inc. is building unique distribution strategies to gain broad penetration in all channels serving its consumer targets in all geographies. The continued mission of Celsius, Inc. is to create healthy refreshment through science and innovation and growth through passion and integrity. For more information about Celsius and Celsius, Inc., please visit http://www.celsius.com. For investor information, please visit http://www.redchip.com.
Forward-Looking Statements
This press release may contain statements, which are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements contain projections of Celsius Holdings' future results of operations, financial position or state other forward-looking information. In some cases you can identify these statements by forward-looking words such as ``anticipate,'' ``believe,'' ``could,'' ``estimate,'' ``expect,'' ``intend,'' ``may,'' ``should,'' ``will,'' and ``would'' or similar words. You should not rely on forward-looking statements because Celsius Holdings' actual results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: our business strategy for expanding our presence in our industry; anticipated trends in our financial condition and results of operation; the impact of competition and technology change; existing and future regulations effecting our business, and changes in general economic conditions in the markets in which we may compete. For further details and a discussion of these and other risks and uncertainties, see our periodic reports including current reports on Form 8-K, quarterly reports on Form 10-QSB and our annual report on Form 10-KSB, furnished to and filed with the Securities and Exchange Commission. Celsius Holdings does not intend to and undertakes no duty to update the information contained in this press release.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday, October 22, 2007
AMGI News Alert
American Mold Guard, Inc. Invites You to Join Its Third Quarter Financial Results On Wednesday, October 31, 2007
Monday October 22, 10:30 am ET
SAN JUAN CAPISTRANO, Calif., Oct. 22, 2007 (PRIME NEWSWIRE) -- American Mold Guard, Inc. (NasdaqCM: AMGI), an industry leader in the field of antimicrobial surface treatment services, announced today that it will host a conference call on Wednesday, October 31, 2007 beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to review third quarter financial results. The call will be open to any interested persons and may contain forward-looking information.
What: American Mold Guard, Inc. Third Quarter Financial Results
When: Wednesday, October 31, 2007 at 4:30 p.m. ET, 1:30 p.m. PT
How: Domestic Dial: 866.510.0676
International Dial: 617.597.5361
Participant Passcode: 46278506
Participants are asked to call the assigned number
approximately 10 minutes before the conference call
begins.
To access the live webcast please visit: http://phx.corporate-ir.net/playerlink.zhtml?c=196351&s=wm&e=1664286
A replay of the conference call will be available two hours after the call and for five business days thereafter (November 7, 2007) by dialing domestically: 888-286-8010 or internationally: 617-801-6888 and entering the following pass code: 11524662.
About American Mold Guard and AMG Scientific, LLC
American Mold Guard, Inc. (NasdaqCM: AMGI), founded in 2002, is the industry leader in the field of antimicrobial surface treatment services. Its mold prevention services are primarily focused on the residential real estate construction industry in California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Mississippi, Texas and Washington with active expansion throughout the United States. Its mold prevention customers include many of the largest national and regional home builders. AMG Scientific, LLC is a wholly owned subsidiary of AMGI. Established in October 2006, AMG Scientific, LLC is focused on providing long-term antimicrobial infection control services to health care facilities and large institutions in an effort to provide an additional intervention safety net in the fight against hospital-acquired infections. Visit: http://www.amgicorp.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company's financial position, results of operations, market position, product and service development and market strategy. These statements may be identified by the fact that they use words or phrases such as ``anticipates,'' ``believes,'' ``estimates,'' ``expects,'' ``intends,'' ``plans,'' ``predicts,'' ``projects,'' ``targets,'' ``will likely result,'' ``will continue,'' ``may,'' ``could'' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, competitive product and service development, the ability to fully develop the company's surface infection control services, future broad market acceptance of antimicrobial surface treatment services, difficulties in raising additional capital in the future, difficulties and delays in establishing the ``Mold Guard'' brand, the impact of the absence of significant proprietary technology underlying our services, changes in the anticipated size or trends of the markets in which we compete, judicial decisions and governmental laws and regulations, and changes in general economic conditions in the markets in which we may compete. For further details and a discussion of these and other risks and uncertainties, see our periodic reports including current reports on Form 8-K, quarterly reports on Form 10-QSB and our annual report on Form 10-KSB, furnished to and filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday October 22, 10:30 am ET
SAN JUAN CAPISTRANO, Calif., Oct. 22, 2007 (PRIME NEWSWIRE) -- American Mold Guard, Inc. (NasdaqCM: AMGI), an industry leader in the field of antimicrobial surface treatment services, announced today that it will host a conference call on Wednesday, October 31, 2007 beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to review third quarter financial results. The call will be open to any interested persons and may contain forward-looking information.
What: American Mold Guard, Inc. Third Quarter Financial Results
When: Wednesday, October 31, 2007 at 4:30 p.m. ET, 1:30 p.m. PT
How: Domestic Dial: 866.510.0676
International Dial: 617.597.5361
Participant Passcode: 46278506
Participants are asked to call the assigned number
approximately 10 minutes before the conference call
begins.
To access the live webcast please visit: http://phx.corporate-ir.net/playerlink.zhtml?c=196351&s=wm&e=1664286
A replay of the conference call will be available two hours after the call and for five business days thereafter (November 7, 2007) by dialing domestically: 888-286-8010 or internationally: 617-801-6888 and entering the following pass code: 11524662.
About American Mold Guard and AMG Scientific, LLC
American Mold Guard, Inc. (NasdaqCM: AMGI), founded in 2002, is the industry leader in the field of antimicrobial surface treatment services. Its mold prevention services are primarily focused on the residential real estate construction industry in California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Mississippi, Texas and Washington with active expansion throughout the United States. Its mold prevention customers include many of the largest national and regional home builders. AMG Scientific, LLC is a wholly owned subsidiary of AMGI. Established in October 2006, AMG Scientific, LLC is focused on providing long-term antimicrobial infection control services to health care facilities and large institutions in an effort to provide an additional intervention safety net in the fight against hospital-acquired infections. Visit: http://www.amgicorp.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company's financial position, results of operations, market position, product and service development and market strategy. These statements may be identified by the fact that they use words or phrases such as ``anticipates,'' ``believes,'' ``estimates,'' ``expects,'' ``intends,'' ``plans,'' ``predicts,'' ``projects,'' ``targets,'' ``will likely result,'' ``will continue,'' ``may,'' ``could'' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, competitive product and service development, the ability to fully develop the company's surface infection control services, future broad market acceptance of antimicrobial surface treatment services, difficulties in raising additional capital in the future, difficulties and delays in establishing the ``Mold Guard'' brand, the impact of the absence of significant proprietary technology underlying our services, changes in the anticipated size or trends of the markets in which we compete, judicial decisions and governmental laws and regulations, and changes in general economic conditions in the markets in which we may compete. For further details and a discussion of these and other risks and uncertainties, see our periodic reports including current reports on Form 8-K, quarterly reports on Form 10-QSB and our annual report on Form 10-KSB, furnished to and filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
DORB News Alert
DOR BioPharma Completes Relocation of Corporate Offices to New Jersey
Tuesday October 2, 7:00 am ET
EWING, NJ--(MARKET WIRE)--Oct 2, 2007 -- DOR BioPharma, Inc. (OTC BB: DORB.OB) ("DOR" or the "Company") announced today that it has relocated its corporate offices from Miami, Florida to Ewing, New Jersey. DOR's new address is Mountain View Office Park, 850 Bear Tavern Road, Ewing, NJ 08628.
According to the Biotechnology Council of New Jersey, New Jersey is rich in resources for the life sciences industry. Inside the state's borders, the life sciences sector includes operations for many of the world's leading pharmaceutical companies and a growing biotechnology cluster. New Jersey currently houses 125 biotechnology companies, making it the fourth-largest biotechnology center in the nation. Coupled with pharmaceutical employees, New Jersey is home to a total of approximately 175,000 employees in the pharmaceutical/biotechnology field.
"Access to experienced pharmaceutical talent in the area was a key factor in our decision to move," stated Christopher J. Schaber, PhD, President and CEO of DOR BioPharma. "Ewing and the central New Jersey area including Princeton offer the ideal combination of industry infrastructure and quality of life that will facilitate the building of the Company in coming years. The ability to easily recruit Sales and Marketing talent as we look forward to potential approval and commercialization of orBec® is of paramount importance to DOR."
About DOR BioPharma, Inc.
DOR BioPharma, Inc. (DOR) is a biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of bone marrow transplantation. DOR has filed an NDA for orBec® with the FDA for the treatment of GI GVHD, and subsequent to supplemental information recently submitted, the FDA has extended the PDUFA (Prescription Drug User Fee Act) date to October 21, 2007. An MAA (Marketing Authorization Application) with the EMEA (European Medicines Evaluation Agency) has also been filed and validated. orBec® may also have application in treating other gastrointestinal disorders characterized by severe inflammation. DOR has recently initiated a development program with its Lipid Polymer Micelle (LPM(TM)) oral drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis, as well as a development program with its oral azathioprine technology for the treatment of oral GVHD.
Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the recently enacted Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin and botulinum toxin. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.
For further information regarding DOR BioPharma, please visit the Company's website located at www.dorbiopharma.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect DOR BioPharma, Inc.'s current expectations about its future results, performance, prospects and opportunities, including statements regarding the potential use of orBec® for the treatment of gastrointestinal GVHD and the prospects for regulatory filings for orBec®. Where possible, DOR has tried to identify these forward-looking statements by using words such as "anticipates," "believes," "intends," or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its technologies will prove to be safe and effective, that its cash expenditures will not exceed projected levels, that it will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the U.S. Government or other countries, that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: because orBec® did not achieve statistical significance in its primary endpoint in the pivotal Phase 3 clinical study (i.e. a p-value of less than or equal to 0.05), the Oncologic Drug Advisory Committee ("ODAC") appointed by the FDA voted that the data supporting orBec® did not show substantial evidence of efficacy by a margin of 7 to 2 for the treatment of GI GVHD, although the FDA is not bound by ODAC's decision, the FDA may not consider orBec® approvable based upon existing studies, orBec® may not show therapeutic effect or an acceptable safety profile in future clinical trials, if required, or could take a significantly longer time to gain regulatory approval than DOR expects or may never gain approval; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; or orBec® may not gain market acceptance; and others may develop technologies or products superior to orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Form 10-QSB and Form 10-KSB. DOR assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, and changes in circumstances or for any other reason.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Tuesday October 2, 7:00 am ET
EWING, NJ--(MARKET WIRE)--Oct 2, 2007 -- DOR BioPharma, Inc. (OTC BB: DORB.OB) ("DOR" or the "Company") announced today that it has relocated its corporate offices from Miami, Florida to Ewing, New Jersey. DOR's new address is Mountain View Office Park, 850 Bear Tavern Road, Ewing, NJ 08628.
According to the Biotechnology Council of New Jersey, New Jersey is rich in resources for the life sciences industry. Inside the state's borders, the life sciences sector includes operations for many of the world's leading pharmaceutical companies and a growing biotechnology cluster. New Jersey currently houses 125 biotechnology companies, making it the fourth-largest biotechnology center in the nation. Coupled with pharmaceutical employees, New Jersey is home to a total of approximately 175,000 employees in the pharmaceutical/biotechnology field.
"Access to experienced pharmaceutical talent in the area was a key factor in our decision to move," stated Christopher J. Schaber, PhD, President and CEO of DOR BioPharma. "Ewing and the central New Jersey area including Princeton offer the ideal combination of industry infrastructure and quality of life that will facilitate the building of the Company in coming years. The ability to easily recruit Sales and Marketing talent as we look forward to potential approval and commercialization of orBec® is of paramount importance to DOR."
About DOR BioPharma, Inc.
DOR BioPharma, Inc. (DOR) is a biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of bone marrow transplantation. DOR has filed an NDA for orBec® with the FDA for the treatment of GI GVHD, and subsequent to supplemental information recently submitted, the FDA has extended the PDUFA (Prescription Drug User Fee Act) date to October 21, 2007. An MAA (Marketing Authorization Application) with the EMEA (European Medicines Evaluation Agency) has also been filed and validated. orBec® may also have application in treating other gastrointestinal disorders characterized by severe inflammation. DOR has recently initiated a development program with its Lipid Polymer Micelle (LPM(TM)) oral drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis, as well as a development program with its oral azathioprine technology for the treatment of oral GVHD.
Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the recently enacted Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin and botulinum toxin. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.
For further information regarding DOR BioPharma, please visit the Company's website located at www.dorbiopharma.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect DOR BioPharma, Inc.'s current expectations about its future results, performance, prospects and opportunities, including statements regarding the potential use of orBec® for the treatment of gastrointestinal GVHD and the prospects for regulatory filings for orBec®. Where possible, DOR has tried to identify these forward-looking statements by using words such as "anticipates," "believes," "intends," or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its technologies will prove to be safe and effective, that its cash expenditures will not exceed projected levels, that it will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the U.S. Government or other countries, that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: because orBec® did not achieve statistical significance in its primary endpoint in the pivotal Phase 3 clinical study (i.e. a p-value of less than or equal to 0.05), the Oncologic Drug Advisory Committee ("ODAC") appointed by the FDA voted that the data supporting orBec® did not show substantial evidence of efficacy by a margin of 7 to 2 for the treatment of GI GVHD, although the FDA is not bound by ODAC's decision, the FDA may not consider orBec® approvable based upon existing studies, orBec® may not show therapeutic effect or an acceptable safety profile in future clinical trials, if required, or could take a significantly longer time to gain regulatory approval than DOR expects or may never gain approval; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; or orBec® may not gain market acceptance; and others may develop technologies or products superior to orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Form 10-QSB and Form 10-KSB. DOR assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, and changes in circumstances or for any other reason.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
GWPC News Alert
Gulf Western Petroleum Announces Third Shamrock Well Test: Miller-Thomas # 1 Flow Tests at 310 MCFD
Monday October 22, 1:00 am ET
HOUSTON, TX, Oct. 22 /PRNewswire-FirstCall/ - Gulf Western Petroleum Corporation ("Gulf Western") (OTCBB: GWPC / Frankfurt: GER), is pleased to announce flow test results of the Miller-Thomas # 1 gas unit. The operator has advised Gulf Western that the Miller-Thomas well stabilized at a flow rate of 310 mcfd with a (FTP) Flowing Tubing Pressure of 1240 psi. The Miller-Thomas well was drilled to a total depth of 3166' and completed from 3128' to 3146'.
The Miller-Thomas #1 is the third well tested in the Shamrock Project. The test results of the first three wells are as follows:
Polinard Lee # 1 - 325 mcfd with FTP 950 psi
Bushmill # 1 - 310 mcfd with FTP 1120 psi
Miller-Thomas # 1 - 310 mcfd with FTP 1240 psi
The Shamrock Project located in Dewitt County, Texas is a five (5) well Frio-age prospect identified through newly acquired 3-D seismic. The Project target formation is the Jameson Sand at 3200 feet. Frio-age wells have proven to be prolific natural gas producers throughout the Texas Gulf Coast region. Typical Frio wells produce at approximately 200 to 300 Mcf per day with estimated total recoverable reserves of approximately 500 million cubic feet to 1 Billion cubic feet. Gulf Western holds a 90% working interest in the Project.
This press release may include forward-looking statements based on the Company's current expectations as to future events. The forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. For example, the extraction and sale of natural gas from the wells involves a number of costs and risks, which may limit our ability to generate cash flow from the wells. In addition, the business of Gulf Western Petroleum Corporation is subject to a number of risks typical of an oil and gas exploration and development company including, among other things, the inherent uncertainties associated with oil and gas exploration; laws, environmental, judicial, regulatory, political and competitive developments in areas in which Gulf Western Petroleum Corporation operates; and technological, mechanical and operational difficulties encountered in connection with Gulf Western Petroleum Corporation's activities.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Monday October 22, 1:00 am ET
HOUSTON, TX, Oct. 22 /PRNewswire-FirstCall/ - Gulf Western Petroleum Corporation ("Gulf Western") (OTCBB: GWPC / Frankfurt: GER), is pleased to announce flow test results of the Miller-Thomas # 1 gas unit. The operator has advised Gulf Western that the Miller-Thomas well stabilized at a flow rate of 310 mcfd with a (FTP) Flowing Tubing Pressure of 1240 psi. The Miller-Thomas well was drilled to a total depth of 3166' and completed from 3128' to 3146'.
The Miller-Thomas #1 is the third well tested in the Shamrock Project. The test results of the first three wells are as follows:
Polinard Lee # 1 - 325 mcfd with FTP 950 psi
Bushmill # 1 - 310 mcfd with FTP 1120 psi
Miller-Thomas # 1 - 310 mcfd with FTP 1240 psi
The Shamrock Project located in Dewitt County, Texas is a five (5) well Frio-age prospect identified through newly acquired 3-D seismic. The Project target formation is the Jameson Sand at 3200 feet. Frio-age wells have proven to be prolific natural gas producers throughout the Texas Gulf Coast region. Typical Frio wells produce at approximately 200 to 300 Mcf per day with estimated total recoverable reserves of approximately 500 million cubic feet to 1 Billion cubic feet. Gulf Western holds a 90% working interest in the Project.
This press release may include forward-looking statements based on the Company's current expectations as to future events. The forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. For example, the extraction and sale of natural gas from the wells involves a number of costs and risks, which may limit our ability to generate cash flow from the wells. In addition, the business of Gulf Western Petroleum Corporation is subject to a number of risks typical of an oil and gas exploration and development company including, among other things, the inherent uncertainties associated with oil and gas exploration; laws, environmental, judicial, regulatory, political and competitive developments in areas in which Gulf Western Petroleum Corporation operates; and technological, mechanical and operational difficulties encountered in connection with Gulf Western Petroleum Corporation's activities.
For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
GWPC Radio Update
RedChip Radio Update: Exclusive Oil & Gas Interview With Gulf Western Petroleum Corporation
Wednesday October 19, 9:00 am ET
RedChip Radio Interviews Sam Nastat, Director and President of Gulf Western Petroleum Corporation
ORLANDO, Fla., Oct. 19, 2007 (PRIME NEWSWIRE) -- RedChip Companies, Inc. today announced that Sam Nastat, President and Director of Gulf Western Petroleum Corpration (OTC BB: GWPC.OB), was featured in an exclusive RedChip Radio(tm) update. The interview included an update on the Company's progress with its Texas Shamrock Frio Project and a discussion on the Company's proven reserves, as well as short and long-term strategic objectives.
RedChip Radio(tm) is a radio news forum that addresses general market and small-cap news and interviews CEOs and executives of prominent small-cap companies.
To hear the interview in its entirety, visit: 10/17/07 Interview with President
About Gulf Western Petroleum Corporation
Gulf Western is focused on the exploration and development of domestic petroleum and natural gas reserves in the United States. The Company currently has a strong portfolio of lease acreage projects in Texas, Kansas and Kentucky. It is also actively seeking out additional oil and gas resource opportunities that would benefit from its range of core competencies. Gulf Western was formed through a merger between Wharton Resources Corp., a development stage company with oil & gas lease acreage in Texas, Kentucky and Kansas, and of Georgia Exploration, Inc.
Gulf Western's primary asset is a high caliber management team with both upstream and midstream segment experience, as well as a proven track record of finding and developing commercial reserves. Pursuant to the merger, the management team is comprised of W. Milton Cox as Chief Executive Officer, Bassam Nastat as President and Don Sytsma as Chief Financial Officer, Treasurer and Secretary. This team has extensive experience in the U.S. oil and gas industry and the ability to attract a steady stream of high quality oil & gas resource opportunities.
About RedChip Companies, Inc.
RedChip Companies is an international small-cap research and financial public relations firm with offices in Beijing and Orlando and affiliates in New York and San Diego. RedChip delivers measurable results for its clients through its extensive international market expertise as well as its comprehensive platform of products: RedChip Research(tm), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences held throughout the United States, and RedChip Radio(tm). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/services.asp.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
Wednesday October 19, 9:00 am ET
RedChip Radio Interviews Sam Nastat, Director and President of Gulf Western Petroleum Corporation
ORLANDO, Fla., Oct. 19, 2007 (PRIME NEWSWIRE) -- RedChip Companies, Inc. today announced that Sam Nastat, President and Director of Gulf Western Petroleum Corpration (OTC BB: GWPC.OB), was featured in an exclusive RedChip Radio(tm) update. The interview included an update on the Company's progress with its Texas Shamrock Frio Project and a discussion on the Company's proven reserves, as well as short and long-term strategic objectives.
RedChip Radio(tm) is a radio news forum that addresses general market and small-cap news and interviews CEOs and executives of prominent small-cap companies.
To hear the interview in its entirety, visit: 10/17/07 Interview with President
About Gulf Western Petroleum Corporation
Gulf Western is focused on the exploration and development of domestic petroleum and natural gas reserves in the United States. The Company currently has a strong portfolio of lease acreage projects in Texas, Kansas and Kentucky. It is also actively seeking out additional oil and gas resource opportunities that would benefit from its range of core competencies. Gulf Western was formed through a merger between Wharton Resources Corp., a development stage company with oil & gas lease acreage in Texas, Kentucky and Kansas, and of Georgia Exploration, Inc.
Gulf Western's primary asset is a high caliber management team with both upstream and midstream segment experience, as well as a proven track record of finding and developing commercial reserves. Pursuant to the merger, the management team is comprised of W. Milton Cox as Chief Executive Officer, Bassam Nastat as President and Don Sytsma as Chief Financial Officer, Treasurer and Secretary. This team has extensive experience in the U.S. oil and gas industry and the ability to attract a steady stream of high quality oil & gas resource opportunities.
About RedChip Companies, Inc.
RedChip Companies is an international small-cap research and financial public relations firm with offices in Beijing and Orlando and affiliates in New York and San Diego. RedChip delivers measurable results for its clients through its extensive international market expertise as well as its comprehensive platform of products: RedChip Research(tm), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences held throughout the United States, and RedChip Radio(tm). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/services.asp.
For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com
CKGT News Alert
China Kangtai Participates in 2007 China National Sugar and Wine Products Trade Fair
Friday October 19, 9:14 am ET
HARBIN, China, Oct. 19 /Xinhua-PRNewswire-FirstCall/ -- China Kangtai Cactus Bio-tech, Inc. (OTC BB: CKGT.OB) participated as an exhibitor in the 2007 National Sugar and Wine Products Trade Fair held in Harbin, China from October 11th through October 15th.
The National Sugar and Wine Products Trade Fair is the largest tradeshow for food and beverage products that contain sugar and alcohol in China. This year's event was unprecedented, with over 100,000 exhibitors and more than 200,000 visitors.
China Kangtai's exhibit highlighted a total of 30 its products in four different categories. Customer response was very positive and the Company received sales orders for over 40 million RMB of product to be fulfilled over the coming year. In addition, the Company received indications of interest from a number of potential customers with whom the Company plans to follow up over the coming weeks.
The Company believes that participating in this event has significantly increased its name recognition expanded the distribution channels for its products, and enabled the Company to begin to develop relationships with potential business partners. The Company plans to participate in similar tradeshows both in China and internationally.
The positive response at this tradeshow also confirmed the Company's belief in the potential market for its cactus-based products in China. The Company is confident that this event will have long term positive benefits for its business that will help ultimately deliver higher returns to its shareholders.
About Cactus and Its Derivative Products
According to The Grand Dictionary of Chinese Medicine and the Compendium of Materia Medica, as well as many certified tests and analyses carried out by the Department of Agriculture and the Institute for Nutrition and Food Safety of the Center of Disease Prevention and Control of China, cacti contain over 18 kinds of amino acid, carbohydrates, chief meal fibrin, carotene, vitamin C, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B12, smoke acid, folacin, calcium, phosphorus, iron, potassium, sodium, magnesium, manganese, copper, zinc, iodine, and selenium. Various cactus products have been shown to provide health benefits and have been used to treat a variety of health issues including, diabetes, adiposity, constipation, cholesterol, high blood pressure, low immunity, and various skin disorders.
China Kangtai owns nearly 400 acres of farmland and grows three species of Mexican cacti and some of the Company's own cloned species. The Company owns an R & D institute that has successfully produced 31 product patents, 15 of which have already been approved. It currently produces and sells four cactus-based product categories: nutraceuticals, which are health and wellness dietary supplements; beverages, including juice, teas, beer, wine, and spirits; packaged foods, such as noodles, biscuits and pickles; and raw and intermediate cactus materials. There are about 36 existing products under these four categories.
Jinjiang Wang, Chief Executive Officer of China Kangtai Cactus Biotech commented, ''Cactus-based products are well received by the market in China and show huge growth potential. China Kangtai will continue to develop new products to meet the demand of the consumers, while penetrating the markets with its existing products.''
Wang concluded, ''Our Company remains focused on the quality and functionality of our products that deliver various health benefits to consumers. These new products will contribute positively to the Company's 2007 performance and beyond, and accelerate its revenue and profit growth. With 15 product patents and 16 pending approval, China Kangtai is the dominant player in the cactus-based consumer product sector."
About China Kangtai Cactus Bio-Tech Inc.
China Kangtai Cactus Bio-Tech, Inc. is market-leading cactus grower and producer of cactus-related products with over 387 acres of plants and an active R&D group that holds 15 product patents and is seeking another 16 in a variety of product categories. China Kangtai's high-quality products are sold throughout China in supermarkets, food stores, hotels and restaurants through a growing distribution network that has currently covered 14 provinces and 4 municipalities.
Cautionary Statement Regarding Forward Looking Information
This press release contains forward-looking information about China Kangtai Cactus Bio-tech that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and China Kangtai Cactus Bio-tech future performance, operations and products.
This forward-looking information should be considered only in connection with "Risk Factors" in China Kangtai Cactus Bio-tech's annual report on Form 10KSB filed with the SEC on April 2, 2007, and its other current and periodic reports filed with the SEC. China Kangtai Cactus Bio-tech assumes no obligations to update any forward-looking statements or information set forth in this press release.
For more information, please contact:
At the Company:
Ren Hu
Vice President
China Kangtai Cactus Bio-tech, Inc.
Tel: +1-201-887-0415
Email: Arenhu@gmail.com
Web: http://www.biocactus.com
Investor Relations:
Jon Cunningham
RedChip Companies, Inc.
Tel: +1-800-RedChip x107
Email: Jon@RedChip.com or Info@RedChip.com
Web: http://www.RedChip.com
Friday October 19, 9:14 am ET
HARBIN, China, Oct. 19 /Xinhua-PRNewswire-FirstCall/ -- China Kangtai Cactus Bio-tech, Inc. (OTC BB: CKGT.OB) participated as an exhibitor in the 2007 National Sugar and Wine Products Trade Fair held in Harbin, China from October 11th through October 15th.
The National Sugar and Wine Products Trade Fair is the largest tradeshow for food and beverage products that contain sugar and alcohol in China. This year's event was unprecedented, with over 100,000 exhibitors and more than 200,000 visitors.
China Kangtai's exhibit highlighted a total of 30 its products in four different categories. Customer response was very positive and the Company received sales orders for over 40 million RMB of product to be fulfilled over the coming year. In addition, the Company received indications of interest from a number of potential customers with whom the Company plans to follow up over the coming weeks.
The Company believes that participating in this event has significantly increased its name recognition expanded the distribution channels for its products, and enabled the Company to begin to develop relationships with potential business partners. The Company plans to participate in similar tradeshows both in China and internationally.
The positive response at this tradeshow also confirmed the Company's belief in the potential market for its cactus-based products in China. The Company is confident that this event will have long term positive benefits for its business that will help ultimately deliver higher returns to its shareholders.
About Cactus and Its Derivative Products
According to The Grand Dictionary of Chinese Medicine and the Compendium of Materia Medica, as well as many certified tests and analyses carried out by the Department of Agriculture and the Institute for Nutrition and Food Safety of the Center of Disease Prevention and Control of China, cacti contain over 18 kinds of amino acid, carbohydrates, chief meal fibrin, carotene, vitamin C, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B12, smoke acid, folacin, calcium, phosphorus, iron, potassium, sodium, magnesium, manganese, copper, zinc, iodine, and selenium. Various cactus products have been shown to provide health benefits and have been used to treat a variety of health issues including, diabetes, adiposity, constipation, cholesterol, high blood pressure, low immunity, and various skin disorders.
China Kangtai owns nearly 400 acres of farmland and grows three species of Mexican cacti and some of the Company's own cloned species. The Company owns an R & D institute that has successfully produced 31 product patents, 15 of which have already been approved. It currently produces and sells four cactus-based product categories: nutraceuticals, which are health and wellness dietary supplements; beverages, including juice, teas, beer, wine, and spirits; packaged foods, such as noodles, biscuits and pickles; and raw and intermediate cactus materials. There are about 36 existing products under these four categories.
Jinjiang Wang, Chief Executive Officer of China Kangtai Cactus Biotech commented, ''Cactus-based products are well received by the market in China and show huge growth potential. China Kangtai will continue to develop new products to meet the demand of the consumers, while penetrating the markets with its existing products.''
Wang concluded, ''Our Company remains focused on the quality and functionality of our products that deliver various health benefits to consumers. These new products will contribute positively to the Company's 2007 performance and beyond, and accelerate its revenue and profit growth. With 15 product patents and 16 pending approval, China Kangtai is the dominant player in the cactus-based consumer product sector."
About China Kangtai Cactus Bio-Tech Inc.
China Kangtai Cactus Bio-Tech, Inc. is market-leading cactus grower and producer of cactus-related products with over 387 acres of plants and an active R&D group that holds 15 product patents and is seeking another 16 in a variety of product categories. China Kangtai's high-quality products are sold throughout China in supermarkets, food stores, hotels and restaurants through a growing distribution network that has currently covered 14 provinces and 4 municipalities.
Cautionary Statement Regarding Forward Looking Information
This press release contains forward-looking information about China Kangtai Cactus Bio-tech that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and China Kangtai Cactus Bio-tech future performance, operations and products.
This forward-looking information should be considered only in connection with "Risk Factors" in China Kangtai Cactus Bio-tech's annual report on Form 10KSB filed with the SEC on April 2, 2007, and its other current and periodic reports filed with the SEC. China Kangtai Cactus Bio-tech assumes no obligations to update any forward-looking statements or information set forth in this press release.
For more information, please contact:
At the Company:
Ren Hu
Vice President
China Kangtai Cactus Bio-tech, Inc.
Tel: +1-201-887-0415
Email: Arenhu@gmail.com
Web: http://www.biocactus.com
Investor Relations:
Jon Cunningham
RedChip Companies, Inc.
Tel: +1-800-RedChip x107
Email: Jon@RedChip.com or Info@RedChip.com
Web: http://www.RedChip.com
Subscribe to:
Posts (Atom)
